Document:

emergentbiosolutionscont

    Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of  information that the registrant treats as private or confidential.  Double asterisks denote omissions.        AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER   UNDER OPAS (15 CFR 700)  RATING PAGE  OF PAGE    1    46  2. CONTRACT (Proc Inst Ident.) NO.  HHSO100201600030C   3.  EFFECTIVE DATE  See Block 20C  4. ACQUISITION (PURCHASE REQUEST   NO.  OS165547  5. ISSUED BY  CODE ASPR-BARDA 6.  ADMINISTERED BY (If other ______ by) CODE ASPR BARDA  ASPR-BARDA  200 Independence Ave., S.W.  Room 640-G  Washington DC 20201   ASPR-BARDA  200 Independence Ave., S.W.  Room 638-G  Washington DC 20201    7. NAME AND ADDRESS OF CONTRACTOR (No., Street, City Country, State and ZIP Code)    EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 1365869  EMERGENT PRODUCT DEVELOPMENT GAITHE  300 PROFESSIONAL DR # 100  GAITHERSBURG MD 208793419  8. DELIVERY    FOB ORIGIN      x  OTHER (See below)  9. DISCOUNT(FOR PROMPT PAYMENT    10. SUBMIT INVOICES  (4 copies unless otherwise specified)   TO THE ADDRESS SHOWN IN   ITEM  CODE 1365869 FACILITY CODE  11. SHIP TO/MARK FOR CODE HHS/OS/ASPR 12.  PAYMENT WILL BE MADE BY CODE PSC    HHS/OS/ASPR  200 C St SW  WASHINGTON DC 20201       Program Support Center  330 Independence Avenue SW  Washington DC 20201    13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION  10 USC 2304(c)(        )      41 USC 253(c) (         )  14. ACCOUNTING AND APPROPRIATION DATA  2016.1990007.26201  15A. ITEM NO 15B. SUPPLIES/SERVICES 15C.  QUANTITY  15D.  UNIT 15E. UNIT PRICE 15F. AMOUNT        Continued        15G. TOTAL AMOUNT OF CONTRACT  $198,705,042.00  16. TABLE OF CONTENTS  (X) SEC DESCRIPTION PAGE(S) (X) SEC.  DESCRIPTION   PART 1 – THE SCHEDULE  PART II – CONTRACT CLAUSES   X A SOLICITATION/CONTRACT FORM 1 X I  CONTRACT CLAUSES 42  X B SUPPLIES OR SERVICES AND PRICES/COSTS 3  PART III – LIST OF DOCUMEMTS, EXHIBITS AND OTHER ATTACH   X C DESCRIPTION/SPECS/WORK STATEMENT 10 X J  LIST OF ATTACHMENTS 46  X D PACKAGING AND MARKING 11  PART IV – REPRESENTATIONS AND INSTRUCTIONS   X E INSPECTION AND ACCEPTANCE 12  K  REPRESENTATIONS, CERTIFICATIONS AND   OTHER STATEMENTS OF OFFERORS    X F DELIVERIES OR PERFORMANCE 13    X G CONTRACT ADMINISTRATION DATA 22  L  INSTRS., CONDS., AND NOTICES TO OFFERORS   X H SPECIAL CONTRACT REQUIREMENTS 26  M  EVALUATION FACTORS FOR AWARD   CONTRACTING OFFICER WILL COMPLETE ITEM 17 (SEALED BID OR NEGOTIATED PROCUREMENT) OR 18 (SEALED BID PROCUREMENT) AS APPLICABLE  17.  X CONTRACTOR’S NEGOTIATED AGREEMENT (Contractor is required to sign this  document and return         2          copies to issuing office.) Contractor agrees to   furnish and deliver all items to perform all the services set forth or otherwise identified   above and on any continuation sheets for the consideration stated herein.  The rights and   obligations of the parties to this contract shall be subject to and governed by the following   documents  (a) this award/contract, (b) the solicitation, if any, and (c) such provisions,   representations, certifications, and specifications, as are attached or incorporated by   reference herein.  (Attachments are listed herein.)  18.  SEALED BID AWARD (Contractor is not required to sign this document.) Your bid on   Solicitation Number   including the additions or changes made by you which additions or changes are set forth   in full above, is hereby accepted as to the items listed above and on any continuation   sheets.  This award consummates the contract which consists of the following   documents  (a) the Government’s solicitation and your bid, and (b) this award/contract.    No further contractual document is necessary. (Block 18 should be checked only when   awarding a sealed-bid contract.)  19A.  NAME AND TITLE OF SIGNER (Type or print)  Adam Havey Adam Havey 20A. NAME OR CONTRACTING OFFICER  BROOKE T. BERNOLD  19B.  NAME OF CONTRACTOR  Emergent BioSolutions    BY  /s/ Adam Havey     (Signature of person authorized to sign)  19C. DATE SIGNED      Sep 28, 2016    20B.  UNITED STATES OF AMERICA      BY     /s/ Brooke Bernold    (Signature of the Contracting Officer)  20C.  DATE SIGNED      9/30/2016  

 

  AUTHORIZED FOR LOCAL REPRODUCTION  Previous edition is NOT usable.       STANDARD FORM 26 (Rev. 5/2011)  Prescribed by GSA  FAR (48 CFR) 53.214(a)  

 

        CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUE  HHSO100201600030C  PAGE OF  2 46  NAME OF OFFEROR OR CONTRACTOR  EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 1365869  ITEM NO.   (A)  SUPPLIES/SERVICES  (B)  QUANTITY  (C)  UNIT  (D)  UNIT PRICE  (E)  AMOUNT  (F)   Tax ID Number:  [**]  DUNS Number:  [**]  Next Generation Anthrax Vaccine  Delivery:  09/27/2016  Appr. Yr.: 2016 CAN: 1990007 Object Class: 26201  FOB: Destination  Period of Performance: 09/30/2016 to 09/29/2021              1 ASPR-16-06550 – CLIN 0001 and CLIN 0002 – Base  contract to Emergent for the Manufacturing  Development and Procurement of AV7909 (FDA   Licensure and Approval/Initial Purchase,  Storage, and Delivery of Product  Obligated Amount:  $198,705,042.00     198,705,042.00         2 CLIN 0001A – Phase II [**] Study of Studies  Required by the FDA [**]  Amount:  $[**] (Option Line Item)     0.00         3 CLIN 0003 Post IV Marketing Commitments  Amount:  $[**] (Option Line Item)     0.00         4 CLIN 0004 (A-H) for Additional Surge Capacity  (Based on [**] doses at the licensure price of  $[**])  Amount:  $[**] (Option Line Item)                                                       0.00  AUTHORIZED FOR LOCAL REPRODUCTION   OPTIONAL FORM 336 (4086)  Sponsored by GSA  FAR (48 CFR) 53 110    

 

  3    PART I – THE SCHEDULE    SECTION B – SUPPLIES OR SERVICES AND PRICES/COSTS    ARTICLE B.1.  BRIEF DESCRIPTION OF SUPPLIES OR SERVICES    Emergent Product Development Gaithersburg Inc. is developing NuThrax vaccine as a next  generation anthrax vaccine. This vaccine is intended to mitigate anthrax as a bio threat against  civilian populations suitable for Post-Exposure Prophylaxis (PEP) as a priority medical  countermeasure.    Under the base period-of-performance, Emergent will complete remaining development activities  necessary to achieve licensure of the vaccine and manufacture and deliver vaccine product into  the Strategic National Stockpile (SNS). The contract options may be exercised to perform  additional studies necessary for licensure, support post-licensure commitments as required by the  FDA, and procure additional treatment courses for the SNS.    The Research and Development (R&D) effort will progress in specific stages that cover the base  performance segment and several options, if necessary, as specified in this contract. The period  of performance for the base period is 60 months.    ARTICLE B.2.  BASE PERIOD      CLIN Period of  Performance  Supplies/ Services Total Est.  Cost  Fixed Fee  (7%)  Total Cost  Plus Fixed Fee      COST REIMBURSEMENT      0001  (Base)  09/30/2016 –  09/29/2021  Licensure, approval, and  clearance of product through  the FDA  [**] [**] [**]      FIRM FIXED PRICE      CLIN Period of  Performance  Supplies/ Services Units (# of  Doses)  Unit Price  ($)  Total ($)  0002  (Base)  09/30/2016 –  09/29/2021  Initial Purchase, Storage, and  Delivery of Product  2,000,000 [**] [**]  Total  CLINS  1&2  09/30/2016 –  09/29/2021  See Above Descriptions   $198,705,042  (Funded)    ARTICLE B.3.  OPTION PRICES    CLIN Period of  Performance  Supplies/ Services Total Est. Cost Fixed Fee Total Cost  Plus Fixed  Fee ($)     COST REIMBURSEMENT      

 

  4    0001A  (Option  Quantity)  [**] Phase II [**] Study or studies  required by the FDA [**]  [**] [**] [**]      CLIN Period of  Performance  Supplies/ Services Total Est. Cost Fixed Fee Total Cost  Plus Fixed  Fee ($)     FIXED PRICE      0003  (Option  Quantity)  [**] Phase IV post marketing  commitments /Requirements  (This is an option that may or  may not be exercised during the  base period as determined by  the need and as established by  the FDA)  N/A N/A [**]         CLIN Period of  Performance  Supplies/ Services Units (# of  Product)  FY 2018  Unit Price  ($)  Total ($)  0004A  (Option  Quantity)  [**] Additional Surge Capacity (EUA) 7,500,000 to  [**]  [**] [**]  0004B  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  7,500,000 to  [**]  [**] [**]  0004C  (Option  Quantity)  [**] Additional Surge Capacity (EUA) [**] [**] [**]  0004D  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  [**] [**] [**]  0004E  (Option  Quantity)  [**] Additional Surge Capacity (EUA) [**] [**] [**]  0004F  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  [**] [**] [**]  0004G  (Option  Quantity)  [**] Additional Surge Capacity (EUA) [**] [**] [**]  0004H  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  [**] [**] [**]    ARTICLE B.4.  LIMITATIONS APPLICABLE TO DIRECT COSTS    a. Items Unallowable Unless Otherwise Provided    Notwithstanding the clause FAR 52.216-7, Allowable Cost and Payment, incorporated in this  contract, the costs of the following items or activities shall be unallowable as direct costs unless  

 

  5    authorized in writing in advance by the Contracting Officer:    1. Acquisition, by purchase or lease, of any interest in real property;    2. Special rearrangement or alteration of facilities;    3. Purchase or lease of any item of general purpose office furniture or office equipment  regardless of dollar value. (General purpose equipment is defined as any items of  

 

  6    personal property which are usable for purposes other than research, such as office equipment and  furnishings, pocket calculators, etc.);    4. Travel to attend general scientific meetings;    5. Unapproved foreign travel;    6. Consultant costs;    7. Subcontracts;    8. Patient care costs;    9. Accountable Government property (defined as both real and personal property with an acquisition cost of  $1,000 or more and a life expectancy of more than two years) and “sensitive items” (defined as items of  personal property, supplies and equipment that are highly desirable and easily converted to personal use),  regardless of acquisition value.    10. Printing Costs (as defined in the Government Printing and Binding Regulations).    11. Light Refreshment and Meal Expenditures - Requests to use contract funds to provide light refreshments and/or  meals to either federal or nonfederal employees must be submitted to the Contracting Officer’s Representative  (COR), with a copy to the Contracting Officer, at least six (6) weeks in advance of the event and are subject to   “HHS Policy on Promoting Efficient Spending: Use of Appropriate Funding for Conferences and Meeting, Food  and Promotional Items and Printing and Publications.” The request shall contain the following information: (a)  name, date, and location of the event at which the light refreshments and/or meals will be provided; (b) a brief  description of the purpose of the event; (c) a cost breakdown of the estimated light refreshments and/or meals  costs; (d) the number of nonfederal and federal attendees receiving light refreshments and/or meals; and (e) if  the event will be held at a government facility.    12. Meeting room or conference space used for face to face meetings with USG staff in the performance of this  contract. Justification for why the meeting cannot be held at a government facility must be provided. COA  requests must be made at least (2) two weeks prior to meeting date.    13. Clinical Trial Insurance    b. Travel Costs    1. During the Base Period total expenditures for travel (transportation, lodging, subsistence, and incidental  expenses) incurred by the Prime Contractor in direct performance of this contract shall not exceed $[**] without  prior advance written approval by the Contracting Officer. Costs must be consistent with FAR 52.247-63 –  Preference for U.S.- Flag Air Carriers.    2. The Contactor shall invoice and be reimbursed for all travel costs in accordance with FAR 31.205-46, Contracts  with Commercial Organizations, Travel Costs.    3. Requests for foreign travel must be submitted at least six weeks in advance and shall contain the following:    (i) Meeting(s) and place(s) to be visited, with costs and dates;  (ii) Names(s) and title(s) of Contractor personnel to travel and their functions in the contract project;  (iii) Contract purpose to be served by the travel;  (iv) How travel of Contractor personnel will benefit and contribute to accomplishing the contract project, or  will otherwise justify the expenditure of AMCG contract funds;  

 

  7    (v) How such advantages justify the costs for travel and absence from the project of more than one person if  such are suggested; and  (vi) What additional functions may be performed by the travelers to accomplish other purpose of the  contact and thus further benefit the project.    ARTICLE B.5.  ADVANCE UNDERSTANDINGS    a. Subcontracts and Consultants    Award of any FFP subcontract or FFP consulting agreement in excess of $150,000 or any cost  reimbursement subcontract or consulting agreement shall not proceed without the prior written consent of  the Contracting Officer via a Contracting Officer Authorization (COA) Letter. COA letters will only be issued  upon review of the supporting documentation required by FAR Clause 52.244-2, Subcontracts. After receiving  written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract and  consulting agreement shall be provided to the Contracting Officer within ten (10) calendar days of full  execution.    b. Site Visits, Inspections and General Audits    At the discretion of the USG and independent of activities conducted by the Contractor, with 48 hours’ notice to  the Contractor, the USG reserves the right to conduct site visits and inspections on an as needed basis,  including collection of product samples and intermediates held by the Contractor, or subcontractor. In case of  subcontractor visits and inspections that are independent of activities conducted by the Contractor, the USG  shall demonstrate cause for such visit and/or inspection. All costs reasonably incurred by the Contractor and  subcontractor for such visit and/or inspection shall be allowable costs.  The Contractor shall coordinate these visits and shall have the opportunity to accompany the USG on any such  visits. Under time-sensitive or critical situations, the USG reserves the right to suspend the 48 hour notice to  the Contractor.  If the Government, Contractor, or other party identifies any issues during an audit, the Contractor shall  capture the issues, identify potential solutions, and provide a report to the Government for review and  acceptance.    • If issues are identified during the audit, Contractor shall submit an issue report to the CO and COR  within 10 business days detailing the finding and corrective action(s) of the audit.  • COR and CO will review the issues report and provide a response to the Contractor within 10  business days.  • Once corrective action is completed, the Contractor will provide a final report to the CO and COR  within a time frame negotiated with the COR in writing after review of the issues report.    c. QA Audits    BARDA reserves the right to participate in QA audits. Upon completion of the QA audit the Contractor shall  provide a report capturing the findings, results, and next steps in proceeding with any potential subcontractors.  If action is requested for a subcontractor, detailed corrective and preventative plans for addressing areas of  non-conformance to ICH and FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit  report, must be provided to BARDA for review and acceptance. The Contractor shall provide responses from  the subcontractors to address these concerns and plans for corrective action execution.    • Contractor shall notify CO and COR of upcoming, ongoing, or recent audits/site visits of  subcontractors as part of weekly communications.  • Contractor shall notify the COR and CO within 5 business days of report completion. The Contractor  shall complete the report within 60 days of the audit/site visit, or as negotiated with the COR in writing  dependent upon the audit findings.  

 

  8    d. Man-in-Plant    At the discretion of the Government and seven calendar (7) days advance notice to the Contractor in writing  from the Contracting Officer, the Government may place a man-in- plant in the Contractor’s facility, who shall  be subject to the Contractor’s policies and procedures regarding security and facility access at all times while in  the Contractor’s facility. As determined by federal law, no Government representative shall publish, divulge,  disclose, or make known in any manner, or to any extent not authorized by law, any information coming to him  in the course of employment or official duties, while stationed in a contractor plant.    e. Emergency Use Authorization (EUA)    The Contractor shall be responsible for generating the data to support the USG’s filing of a Pre-Emergency  Use Authorization (Pre-EUA) package for use of the product prior to FDA licensure or approval during a  declared emergency, declared potential emergency, or identification of material threat under an Emergency  Use Authorization (EUA).    The Contractor commits to supporting the potential use of the product under a pre-EUA package as submitted  by BARDA or the CDC/SNS. The Contractor shall supply BARDA or the CDC/SNS with the data needed to  support such a submission, including expanded access INDs, right to hold product, right of reference to the  Contractor's Investigational New Drug (IND), or other application that contains the supporting data. The  Contractor shall address any FDA comments on all pre-EUA packages as applicable. The Contractor shall  maintain and update, as required by the FDA, all required regulatory documentation (investigator brochure,  regulatory binder, etc.), that will be used to support use          under EUA and approval/licensure.    Any product which has not received FDA approval or licensure, but has completed submission of a Pre-EUA  package deemed acceptable by the FDA and has met the two  (2) criteria listed below may be considered for procurement at the discretion of the USG. The Contractor would  be required to demonstrate the two (2) essential criteria listed below for consideration of procurement of any  unapproved products by seeking a COA. The COA shall include a product delivery schedule for consideration  and documentation of the following:    • Substantial evidence, including a validated process, of the Contractor’s ability to manufacture a  product that would be identical to the commercial scale as required for product approval or licensure. A  clear understanding of the outstanding risks, if any, for approval or licensure must be demonstrated.    • Completion of non-clinical and clinical studies with substantial evidence of safety and efficacy for the  indicated use. A list of outstanding activities and targets for completion, adverse events/safety profile  which do not pose unusual risks or challenges for FDA approval or licensure shall be provided.      A tentative delivery schedule of product delivery to the inventory (acceptable as in the Quality Agreement) shall  be required as part of the COA. The delivery schedule shall be updated periodically as necessary.    For information concerning EUA, please consult   http://www.fda.gov/RegulatoryInformation/Guidances/ucm125127     and   http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/   MCMLegalRegulatoryandPolicyFramework/ucm182568.htm  

 

  9    f. Sharing of contract deliverables within United States Government (USG)    In an effort to build a robust medical countermeasure pipeline through increased collaboration, BARDA may  share technical deliverables with USG entities responsible for Medical Countermeasure Development. In  accordance with recommendations from the Public Health Emergency Medical Countermeasure Enterprise  Review, agreements established in the Integrated Portfolio’s Portfolio Advisory Committee (PAC) Charter, and  agreements between BARDA and the Department of Defense and the National Institutes of Health, BARDA  may share technical deliverables and data created in the performance of this contract with colleagues within the  Integrated Portfolio. This advance understanding does not authorize BARDA to share financial information  outside HHS.  The Contractor is advised to review the terms of FAR 52.227-14, Rights in Data – General,  regarding the Government’s rights to deliverables submitted during performance as well as the Government’s  rights to data contained within those deliverables.    g. Overtime Compensation    No overtime (premium) compensation is authorized under the subject contract. Billing of actual hours should be  limited to total productive hours in a month.    h. Option CLINS    If procurement for CLIN 4 occurs after FY 2018, the following chart illustrates the dose prices to be used:    Units (# of Doses) FY 2019 Unit  Price ($)  FY 2020 Unit  Price ($)  FY 2021 Unit  Price ($)  7,500,000 to  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]    The USG reserves the right to re-negotiate the option CLINS based on availability of funds and feedback  received from the FDA.    i. Contract Number Designation    On all correspondence submitted under this contract, the Contractor agrees to clearly identify the contract  number that appears on the face page of the contract as follows:    HHSO100201600030C  

 

  10    j. Quality Agreement    The Quality Agreement shall define, establish, and document the responsibilities of both the Contractor and the  USG (i.e. – CDC/SNS-Quality Control and BARDA) for event- driven and product shipping, receiving,  acceptance into the inventory and/or custody by the USG. These documents shall be drafted, approved, and  signed by all parties prior to the commencement of product procurement and acceptance, transport and  custody of the product under the CDC/SNS. The Contractor shall provide documentation and resolution for all  concerns raised by USG and commits to cooperation in execution of this agreement.  

 

  11    SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT    ARTICLE C.1.  STATEMENT OF WORK    Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified  personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the  Statement of Work dated September 30, 2016 set forth in SECTION J - List of Attachments, attached hereto and made  a part of the contract.    ARTICLE C.2.  REPORTING REQUIREMENTS    See Section F for specific reporting requirements.    All reports required herein shall be submitted in electronic format. All paper/hardcopy documents/reports submitted  under this contract shall be printed or copied, double-sided, on at least 30 percent post-consumer fiber paper,  whenever practicable, in accordance with FAR 4.302(b).    ARTICLE C.3.  TWICE MONTHLY CONFERENCE CALLS    A conference call between the Contracting Officer’s Representative (COR) and the Contractor’s Project  Leaders/delegates and designees shall occur twice-monthly or as directed by the Contracting Officer and Contracting  Officer’s Representative. During this call the Contractor’s Project Leaders/delegates and designees will discuss the  activities since the last call, any problems that have arisen and the activities planned until the next call takes place. The  Contractor’s Project Leaders/delegates may choose to include other key personnel on the conference call to give  detailed updates on specific projects or this may be requested by the Contracting Officer’s Representative.    ARTICLE C.4.  PROJECT MEETINGS    The Contractor shall participate in Project Meetings to coordinate the performance of the contract, as requested by the  Contracting Officer’s Representative. These meetings may include face-to- face meetings with AMCG/BARDA in  Washington, D.C. and at work sites of the Contractor. Such meetings may include, but are not limited to, meetings of  the Contractor to discuss study designs, site visits to the Contractor’s facilities, and meetings with the Contractor and  HHS officials to discuss the technical, regulatory, and ethical aspects of the program. Subject to the data rights  provisions in this contract, the Contractor will provide data, reports, and presentations to groups of outside experts and  USG personnel as required by the Contracting Officer and Contracting Officer’s Representative in order to facilitate  review of contract activities.  

 

  12    SECTION D – PACKAGING, MARKING AND SHIPPING    All deliverables required under this contract shall be packaged, marked and shipped in accordance with Government  specifications. At a minimum, all deliverables shall be marked with the date, contract number and Contractor name.  The Contractor shall guarantee that all required materials shall be delivered in immediate usable and acceptable  condition.  

 

  13    SECTION E – INSPECTION AND ACCEPTANCE    The Contracting Officer or the duly authorized representative will perform inspection and acceptance of materials and  services to be provided under this contract.    For the purpose of this SECTION E, the designated Contracting Officer’s Representative (COR) is the authorized  representative of the Contracting Officer. The COR will assist in resolving technical issues that arise during  performance. The COR however is not authorized to change any contract terms or authorize any changes in the  Statement of Work or modify or extend the period of performance, or authorize reimbursement of any costs incurred  during performance.  The Contractor is advised to review FAR 52.243-1 Changes – Fixed Price Contracts Alternate V and FAR 52.243-2  Changes-Cost reimbursement contracts Alternative V, which is incorporated by reference into this contract in  ARTICLE I.1.    Inspection and acceptance will be performed at:    Office of Acquisition Management, Contracts, and Grants (AMCG) Office of the Assistant  Secretary for Preparedness and Response  U.S. Department of Health and Human Services 200 C St. SW  Washington, D.C. 20024    Acceptance may be presumed unless otherwise indicated in writing by the Contracting Officer or the duly authorized  representative within 30 days of receipt.    The contract incorporates the following clause by reference with the same force and effect as if it were given in full text.  Upon request, the Contracting Officer will make its full text available.    FAR 52.246-4, Inspection of Services - Fixed Price (August 1996)    FAR 52.246-5, Inspection of Services - Cost-Reimbursement (April 1984)    FAR 52.246-9, Inspection of Research and Development (Short Form) (April 1984) FAR 52.246-16,  Responsibility for Supplies (April 1984)  

 

  14    SECTION F – DELIVERIES OR PERFORMANCE    ARTICLE F.1.  PERIOD OF PERFORMANCE    The period of performance for this contract shall be from September 30, 2016 through September 29, 2021. The period  of performance for the base period of this contract shall be consistent with the dates set forth in SECTION B. If the  Government exercises option(s), the period of performance will be extended as described under in SECTION B of this  contract.    ARTICLE F.2.  REPORTING REQUIREMENTS    In all cases the reports are intended to provide sufficient detail to understand the Contractor's approach and progress to  addressing the technical requirements. The reports supplement, and do NOT replace, routine (i.e. daily) communication  between the COR and project manager and/or their designee(s) regarding project plans and progress.    A. Monthly Progress Report    This report shall include a description of the activities during the reporting period and the activities planned for  the ensuing reporting period. The first reporting period consists of the first full month of performance plus any  fractional part of the initial month. Thereafter, the reporting period shall consist of each calendar month.    The Contractor shall submit a Monthly Progress Report on or before the 15th calendar day following the last  day of each reporting period and shall include the following:    Title Page: The title page for this report shall include the contract number and title; the type of report and  period that it covers; the Contractor's name, address, telephone number, fax number, and e-mail address; and  the date of submission.    Distribution List: A list of individuals receiving the Technical Progress report.    Progress:    SECTION I - An introduction covering the purpose and scope of the contract effort. SECTION II Part A:  SUMMARY - A description or table summarizing ongoing activities.  SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE – This section  shall include a description of all meetings, conference calls, etc. that have taken place during the reporting  period. Include progress on administration and management issues (e.g. evaluating and managing  subcontractor performance and personnel changes).  Please include all Quality Management System, Quality Control, and Quality Assurance updates as part of this  report or as requested by the COR.    SECTION II Part C: TECHNICAL PROGRESS – This section shall document the results of work completed  and costs incurred during the period covered in relation to the proposed progress, effort, and budget. The  report shall be in sufficient detail to explain comprehensively the results achieved.    SECTION II Part D: ISSUES – This section shall include a description of problems encountered and proposed  corrective action; differences between planned and actual progress; why the differences have occurred and  what corrective actions are planned; and if a project activity is delinquent, then what corrective action steps are  planned.  Revised timelines shall be provided.    SECTION II Part E: PROPOSED WORK – This section shall include a summary of work proposed as a rolling  three (3) month forecast for the next reporting period, by a certain date, and by whom.  

 

  14    SECTION II Part F: MANUFACTURING AND SUPPLY CHAIN MANAGEMENT – This  section shall include a summary of the manufacturing and supply-chain related activities. Also include in this  section updates to the production plan, capacity projections, stability results, inventory and  shipment/distribution information.    Invoices: Summary of any invoices submitted during the reporting period.    A Monthly Progress Report will not be required in the same months that Annual or Final Technical Progress  Reports are due.    B. Annual Progress Report    This report shall include a summation of the activities during the reporting period, and the activities planned for  the ensuing reporting period. The first reporting period consists of the first full year of performance plus any  fractional part of the initial year. Thereafter, the reporting period shall consist of each calendar year.    The Contractor shall submit an Annual Progress Report on or before the 30th calendar day following the last  day of each reporting period and shall include the following:    Title Page: The title page for this report shall include the contract number and title; the type of report and  period that it covers; the Contractor's name, address, telephone number, fax number, and e-mail address;  and the date of submission.    Distribution List: A list of individuals receiving the Technical Progress report.    Progress:    SECTION I - An introduction covering the purpose and scope of the contract effort. SECTION II Part A:  SUMMARY - A description or table summarizing ongoing activities.  SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE – This section  shall include a description of all meetings, conference calls, etc. that have taken place during the reporting  period. Include progress on administration and management issues (e.g. evaluating and managing  subcontractor performance and personnel changes).  Please include all Quality Management System, Quality Control, and Quality Assurance updates as part of this  report or as requested by the COR.    SECTION II Part C: TECHNICAL PROGRESS – This section shall document the results of work completed and  costs incurred during the period covered in relation to proposed progress, effort, and budget. The report shall  be in sufficient detail to explain comprehensively the results achieved.    SECTION II Part D: ISSUES – This section shall include a description of problems encountered and proposed  corrective action; differences between planned and actual progress; why the differences have occurred and  what corrective actions are planned; and if a project activity is delinquent, then what corrective action steps are  planned.  Revised timelines shall be provided.    SECTION II Part E: PROPOSED WORK – This section shall include a summary of work proposed as an  annual forecast for the next reporting period, by a certain date, and by whom.    SECTION II Part F: MANUFACTURING AND SUPPLY CHAIN MANAGEMENT – This  section shall include a summary of the manufacturing and supply-chain related activities. Also include in this  section updates to the production plan, capacity projections, stability results, inventory and  shipment/distribution information.    Invoices: Summary of any invoices submitted during the reporting period.  

 

  15    An Annual Progress Report will not be required for the period when the Final Technical Progress Report is due.    C. Draft Final Report and Final Report    These reports are to include a summation of the work performed and results obtained for execution of various  studies or technical work packages during the entire contract period of performance. This report shall be in  sufficient detail to describe comprehensively the results achieved. The Draft Final Progress Report shall be due  forty-five (45) calendar days prior to the expiration date of the contract and the Final Progress Report is due on  or before the expiration date of the contract. The report shall conform to the following format:    Title Page: The title for these reports shall include the contract number and title; the type of report and period  that it covers; the Contractor's name, address, telephone number, fax number, and e-mail address; and the  date of submission.    Distribution List: A list of individuals receiving the Technical Progress report.    Progress:    SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract effort including a  summary of the major accomplishments relative to the specific activities set forth in the Statement of Work.    SECTION II: RESULTS - A detailed description of the work performed and the results obtained including all  expenses for the entire contract period of performance.    D. FDA Regulatory Agency Correspondence, Meeting Summaries, and Submissions.    a. Within five business days of any formal meeting with the FDA or other regulatory agency, the  Contractor shall forward the initial draft minutes to BARDA. The Contractor shall forward the final  minutes when available.    b. Within five business days of any informal meeting with the FDA or other regulatory agency, the  Contractor shall provide a formal contact report to BARDA. The Contractor shall forward the final  minutes when available and if applicable.    c. The Contractor shall forward the dates and times of any formal meeting with the FDA and other  regulatory agencies to BARDA as soon as the meeting times are known and make arrangements for  appropriate BARDA staff to attend the meetings.    d. The Contractor shall provide BARDA the opportunity to review and comment upon any documents to be  submitted to the FDA or other regulatory agency. The Contractor shall provide BARDA with five (5)  business days in which to review and provide comments back to the Contractor prior to the Contractor’s  submission to the FDA.    e. The Contractor shall make Standard Operating Procedures (SOPs) available upon request from  COR.    f. The Contractor shall provide raw data and/or specific analysis of data generated with USG funds upon  request from the COR.    g. The Contractor shall notify the Contracting Officer’s Representative and Contracting Officer within 24  hours of all site visits/audits conducted by the FDA or any other regulatory agency. The Contractor  shall provide the USG with an exact copy (non-redacted) of the FDA Form 483 and the Establishment  Inspection Report (EIR). The Contractor shall provide the Contracting Officer’s  

 

  16    Representative and Contracting Officer copies of the plan for addressing areas of non-conformance to  FDA regulations for GLP guidelines as identified in the audit report, status updates during the plans  execution, and a copy of all final responses to the FDA. The Contractor shall also provide redacted  copies of any FDA audits received from subcontractors that occur as a result of this contract or for this  product. The Contractor shall make arrangements with the COR for the appropriate BARDA  representative(s) to be present during the final debrief by the regulatory inspector.    E. Other Requirements/Deliverables    a. Integrated Master Project Plan  The Contractor shall provide an Integrated Master Project Plan (including tabular and Gantt forms) to  BARDA that clearly indicates the critical path to annual deliverables and Work Breakdown Structure  (WBS) elements. Attention shall be placed on providing sufficient turnaround time for the USG  (BARDA, FDA, and CDC) for review of critical documentation. The Contractor shall integrate to  demonstrate interdependencies among all CLINS. The Integrated Master Project Plan shall be  incorporated into any potential contract and will be used to monitor performance of the contract. This  report shall be due within 90 days of contract award. Updates shall be due as requested by the COR or  Alternate COR.    i. Critical Path Milestones  The Integrated Master Project Plan shall outline key, critical path milestones, with “Go/No Go”  decision criteria (entrance and exit criteria for each phase of the project). This report shall be  due within 90 days of contract award. Updates shall be due as requested by the COR or  Alternate COR.    ii. Work Breakdown Structure  The USG has provided a Contract Work Breakdown Structure (CWBS) template (See   http://www.phe.gov/about/amcg/contracts/Pages/toolkit.aspx) and the Contractor shall further  delineate the CWBS to Level 5 as part of their Integrated Master Project Plan. The WBS shall  be discernable and consistent. BARDA may require Contractor to furnish WBS data at the  work package level or at a lower level if there is significant complexity and risk associated with  the task. This report shall be due within 90 days of contract award. Updates shall be due as  requested by the COR or Alternate COR.    iii. Risk Mitigation Plan/Matrix  The Contractor shall develop and maintain a risk management plan that highlights potential  problems and/or issues that may arise during the life of the contract, their impact on cost,  schedule and performance, and appropriate remediation plans. This plan shall reference  relevant WBS/SOW elements where appropriate. The USG has provided a Risk Mitigation  Matrix template (See http://www.phe.gov/about/amcg/contracts/Pages/toolkit.aspx) to be  completed by any prospective Contractor. This report shall be due within 90 days of contract  award. Updates shall be due as requested by the COR or Alternate COR.    b. Technology Packages  Technology packages developed under the contract that includes complete protocols must be  submitted at the request of the BARDA Contracting Officer’s Representative. See FAR clauses 52.227- 11, Patent Rights-Ownership by the Contractor, and 52.227-14, Rights in Data. This report shall be due  upon request from the COR or Alternate COR.  

 

  17    c. Experimental Protocols  The Contractor shall submit to the COR all protocols and associated study/experiment/test plans prior  to the execution of any non-clinical animal study or clinical study for BARDA approval or upon request  by the COR or Alternate COR when required. Approval must be provided in writing by the COR or  Alternate COR prior to the execution of the study.    d. Annual/Final Invention Report  All reports and documentation required by FAR Clause 52.227-11, Patent Rights- Ownership by the  Contractor, including, but not limited to, the invention disclosure report, the confirmatory license, and  the Government support  certification. An Annual Invention Report shall be due on or before the 30th calendar day after the  completion of each reporting period. A Final Invention  Report (see FAR 27.303 (b)(2)(ii)) shall be due on or before the expiration date of the contract. If no  invention is disclosed or no activity has occurred on a previously disclosed invention during the  applicable reporting period, a negative report shall be submitted to the Contracting Officer.    e. Publications  Any manuscript or scientific meeting abstract containing data generated under this contract must be  submitted to COR for review prior to submission.  Publications are due within 10 business days for manuscripts and 5 business days for abstracts prior  to public release.    f. Press Releases  The Contractor agrees to accurately and factually represent the work conducted under this contract in  all press releases. The Contractor shall ensure the Contracting Officer has received and approved an  advanced copy of any press release not less than five (5) business days prior to the issuance of any  potential press release.    g. Incident Security Report  The Contractor shall report to the government any activity; or incident that is in violation of  established security standards; or indicates the loss or theft of government products. Reports shall be  due within 24 hours after occurrence of an activity or incident.    h. Security Plan  The Contractor shall submit a draft security plan within 90 days of contract  award. A detailed security  plan with any updates shall be submitted for approval at least three (3) months prior to the initiation of  product procurement with proper documentation. The Contractor shall cooperate with USG  representatives to develop a sustainable security plan to ensure continued security of the premises.  Security plan updates are required when an incident security report has been filed.    F. Earned Value Management System Plan    a. Earned Value Management System Plan:    Subject to the requirements under HHSAR Clause 352.234-3, the Contractor shall use principles of  Earned Value Management System (EVMS) in the management of this contract (include this plan as  part of the monthly, annual, and final reports). The Seven Principles are:    I. Plan all work scope for the program to completion.    II. Break down the program work scope into finite pieces that can be assigned to a  responsible person or organization for control of technical, schedule, and cost  objectives.  

 

  18   III. Integrate program work scope, schedule, and cost objectives into a performance  measurement baseline plan against which accomplishments may be measured.  Control changes to the baseline.    IV. Use actual cost incurred and recorded in accomplishing the work performed.    V. Objectively assess accomplishments at the work performance level.  VI. Analyze significant variances from the plan, forecast impacts, and prepare an estimate  at completion based on performance to date and work to be performed.    VII. Use  earned  value  information  in  the  company’s  management processes.    VIII. Elements of EVMS shall be applied to all CLINs as part of the Integrated Master  Project Plan, the Contractor shall submit  a written summary of the management  procedures that it will establish, maintain and use to comply with EVMS requirements.    b. Performance Measurement Baseline Review (PMBR):    The Contractor shall submit a PMBR plan electronically via email to the CO and COR for a PMBR to  occur within 90 days of contract award. At the PMBR, the Contractor and BARDA shall mutually agree  upon the budget, schedule and technical plan baselines (Performance Measurement Baseline). These  baselines shall be the basis for monitoring and reporting progress throughout the life of the contract. The  PMBR is conducted to achieve confidence that the baselines accurately capture the entire technical  scope of work, are consistent with contract schedule requirements, are reasonably and logically planned,  and have adequate resources assigned. The goals of the PMBR are as FOLLOWS:    I. Jointly assess areas such as the Contractor’s planning for complete coverage of the  SOW, logical scheduling of the work activities, adequate resources, and identification  of inherent risks.    II. Confirm the integrity of the Performance Measurement Baseline (PMB).    III. Foster the use of EVM as a means of communication.    IV. Provide confidence in the validity of Contractor reporting    V. Identify risks associated with the PMB.    VI. Present any revised PMBs for approval.    VII. Present an Integrated Master Schedule: The Contractor shall deliver an initial program  level Integrated Master Schedule (IMS) that rolls up all time-phased WBS elements  down to the activity level. This IMS shall include the dependencies that exist between  tasks. This IMS will be agreed to and finalized at the PMBR. DI- MGMT-81650 may be  referenced as guidance in creation of the IMS (see http://www.acq.osd.mil/pm/).    VIII. Present the Risk Management Plan.  

 

  19   c. Integrated Master Schedule    The Contractor shall provide a program Integrated Master Schedule (IMS) with monthly status updates  (e.g. % complete with program tasks).    Initial IMS due thirty (30) days after award. Monthly status updates are due the 20th day of the month  after the end of each month.    The Integrated Master Schedule shall be incorporated into the contract, and shall be used to monitor  performance of the contract. The Contractor shall include the key milestones and Go/No Go decision  gates. The Contractor shall include BARDA Portfolio Management Milestones (See the AMCG Business  Toolkit for a description and sample (http://www.phe.gov/about/amcg/contracts/Pages/toolkit.aspx) in  their IMS and provide monthly updates within their IMS. This IMS shall include the following fields at a  minimum; baseline start and finish, forecast start and finish, actual start and finish, predecessor and/or  successor. The Contractor shall deliver the Integrated Master Schedule, viewed at the work package  level in MS Project file format    d. Earned Value Contract Performance Report (EV-CPR)    a. The Offeror shall deliver an Earned Value Contract Performance Report (CPR) on a monthly basis  per the instruction in DI-MGMT-81466A (see  http://www.acq.osd.mil/pm/). The Contractor shall  provide Format 1, Format 3, and Format 5 only. Format 1 will be reported at the Work Breakdown  Structure level 3 agreed to by BARDA and the Contractor.    b. EV Variance thresholds will be negotiated with the Contractor post-award but for planning purposes will  likely be (+/- 10% and $30,000). In conjunction with the CPR, the Contractor shall provide a monthly  update to the IMS with up to date performance data and shall include actual start/finish and projected  start / finish dates.    c. The supplemental monthly CAP report shall contain, at the work package level, time phased budget  (budgeted cost of work scheduled (BCWS)), earned value (budgeted cost of work performed  (BCWP)), and actual costs of work performed (ACWP) as captured in the Contractor’s EVM systems.    d. The Contractor and BARDA shall participate in regular meetings to coordinate and oversee the  contracting effort as requested by the COR. Such meetings may include, but are not limited to, site  visits to the Contractor’s and/or  subcontractor’s facilities, meetings with individual Contractors and other HHS officials to discuss the  technical, regulatory, and ethical aspects of the program. The Contractor shall provide data, reports,  and presentations to groups of outside experts and USG personnel and Government-contracted  subject matter experts as required by the BARDA COR in order to facilitate review of contract  activities.    e. The Contractor shall provide a list of individuals to serve as primary and secondary points of contact  who will be available 24 hours a day, seven days a week, to be notified in case of a public health  emergency.    ARTICLE F.3.  DELIVERIES    Successful performance of the final contract shall be deemed to occur upon performance of the work set forth in the  Statement of Work dated September 30, 2016, set forth in SECTION J - List of Attachments of this contract and upon  delivery and acceptance by the Contracting Officer, or the duly authorized representative, of the following items in  accordance with the stated delivery schedule below:  

 

  20      Item  No.  Description Addresses Deliverable Schedule  1 Monthly Progress  Report  CO: (1) electronic copy    COR: (1) electronic  copy  Reports are due on or before  the 15th of each month  following the end of each  reporting period.  2 Annual Progress  Report  CO: (1) electronic copy    COR: (1) electronic  copy  Reports are due on or before  the 30th calendar day  following the end of each  reporting period.  3 Draft Final Progress  Report  CO: (1) electronic copy    COR: (1) electronic  copy  Report is due 45 Calendar  days prior to the expiration  date of the contract.  4 Final Progress  Report  CO: (1) electronic copy    COR: (1) electronic  copy  Report is due on or before  the expiration date of the  contract.  5 FDA/ Regulatory  Agency  Correspondence  and Meeting  Summaries  COR: (1) electronic  copy  Reports are due within 5  business days of each  meeting for Contractor’s  minutes, upon receipt of  minutes from FDA/ regulatory  agency, and upon request  from the COR or Alternate  COR.  6 Integrated Master  Project Plan  -Critical Path  Milestones  - Work Breakdown  Structure  - Risk Mitigation  Plan/Matrix  COR: (1) electronic  copy  Report is due within 90 days  of contract award. Updates  are due as requested by the  COR or Alternate COR.  7 Technology  Packages  COR: (1) electronic  copy  Upon request from the COR  or Alternate COR.  8 Experimental  Protocols for non-  clinical animal  studies or clinical  studies  COR: (1) electronic  copy  Upon request from the COR  or Alternate COR. Written  approval from the COR or  Alternate COR is required  prior to the execution of the  study.  9 Annual/Final  Invention Report  CO: (1) electronic copy    COR: (1) electronic  copy  An Annual Invention Report is  due on or before the 30th  calendar day after the  completion of each reporting  period. A Final Invention  Report is due on or before  the expiration date of the  

 

  21         contract.  10 Publications COR: (1) electronic  copy  Reports are due within 10  business days for  manuscripts and 5 business  days for abstracts.  11 Press Releases CO: (1) electronic copy    COR: (1) electronic  copy  Reports/Notices are due for  approval to the CO not less  than five (5) business days  prior to the issuance of any  potential press release.  12 Incident Security  Report  CO: (1) electronic copy    COR: (1) electronic  copy  Reports are due within 24  hours after occurrence of an  activity or incident.  13 Security Plan CO: (1) electronic copy    COR: (1) electronic  copy  Draft report is due within 90  days of contract award.  Updates are due at least 3  months prior to product  procurement or as requested  by the COR or Alternate  COR.  14 Earned Value  Management  Requirements  CO: (1) electronic copy    COR: (1) electronic  copy  As detailed in Section F.2  Reporting Requirements,  subpart -F.    Email Addresses: CO – [**]  COR – [**]    ARTICLE F.4.  FEDERAL ACQUISITION REGULATION CLAUSES INCORPORATED BY REFERENCE, FAR  52.252-2 (FEBRUARY 1998)    This contract incorporates the following clause(s) by reference, with the same force and effect as if it were given in full  text. Upon request, the Contracting Officer will make its full text available.  The full text of each clause may be accessed electronically at this address: http://www.acquisition.gov/far.    FAR 52.242-15, Stop Work Order (August 1989)  FAR 52.242-15, Alternate 1 (April 1984) is applicable to this contract.  

 

  22    SECTION G - CONTRACT ADMINISTRATION DATA    ARTICLE G.1.  CONTRACTING OFFICER    The following Contracting Officer (CO) will represent the Government for the purpose of this contract:    [**] DHHS/OS/ASPR/AMCG 200 C St.  Washington, D.C. 20024    a. The Contracting Officer (CO) is the only individual who can legally commit the Government to the expenditure of  public funds. No person other than the CO can make any changes to the terms, conditions, general provisions,  specifications or other requirements of this contract.    b. The Contracting Officer (CO) is the only person with authority to act as agent of the Government under this contract.  Only the CO has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the  period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any  costs incurred during the performance of this contract; or (5) otherwise change any terms and conditions of this  contract.    c. No information, other than that which may be contained in an authorized modification to this contract duly issued  by the CO, shall be considered grounds for deviation from this contract.    d. The Government may unilaterally change its CO designation.    ARTICLE G.2.  CONTRACTING OFFICER'S REPRESENTATIVE (COR)    The following Contracting Officer's Representative (COR) will represent the Government for the purpose of this  contract:    [**]        Contracting Officer's Representative   Biomedical Advanced Research and Development Authority (BARDA)   Office of the Assistant Secretary for Preparedness and Response   Department of Health and Human Services  [**]    Mailing Address: 200 C St.  Washington, D.C. 20024   Alternate COR:  [**]  Alternate Contracting Officer’s Representative (COR)  Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant  Secretary for Preparedness and Response Department of Health and Human Services  [**]    Mailing Address: 200 C St.  Washington, D.C. 20024  

 

  23   The COR is responsible for:  a. Monitoring the Contractor's technical progress, including the surveillance and assessment of performance  and recommending to the Contracting Officer changes in requirements;  b. Assisting the Contracting Officer in interpreting the statement of work and any other technical  performance requirements;  c. Performing technical evaluation as required;  d. Performing technical inspections and assisting the Contracting Officer in acceptances of deliverables  required by this contract; and  e. Assisting in the resolution of technical problems encountered during performance.  f. The Government may unilaterally change its COR designation(s).    ARTICLE G.3.  KEY PERSONNEL    The key personnel specified in this contract are considered to be essential to work performance. At least 30 days prior  to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual  must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the  Contracting Officer and shall submit comprehensive justification for the diversion or replacement request (including  proposed substitutions for key personnel) to permit evaluation by the Government of the impact on performance  under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent  of the Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of  the Contractor or Government.    The following individuals are considered to be essential to the work being performed hereunder:    Name Title  [**] [**]  [**] [**]  [**] [**]  [**] [**]  [**] [**]  [**] [**]  [**] [**]    ARTICLE G.4.  INVOICE SUBMISSION    a. The Contractor shall submit an electronic copy of contract monthly invoices/financial reports to the  Contracting Officer as defined above, in ARTICLE G of this contract.  b. Contractor invoices/financial reports shall conform to the form, format, and content requirements of the  instructions for Invoice/Financing requests made a part of the contract at Section J, Attachments 2 &  3.    c. Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show  any amounts suspended by the Government.    d. The Contractor agrees to immediately notify the Contracting Officer in writing if there is an anticipated  overrun (any amount) or unexpended balance (greater than 10 percent) of the estimated costs for the base  period or any options for additional quantities (See estimated costs under Articles B.2 and B.3) and the  reasons for the variance. Also refer to the requirements of FAR Clause 52.232-20, Limitation of Cost.    e. The Contractor shall submit an electronic copy of the payment request to the approving official instead of a  paper copy. The payment request shall be transmitted as an attachment via e-mail to the address listed above  in one of the following formats: MSWord,  

 

  24    MS Excel, or Adobe Portable Document Format (PDF). Only one payment request shall be  submitted per e-mail and the subject line of the e-mail shall include the Contractor's name,  contract number, and unique invoice number.    f. All invoice submissions shall be in accordance with FAR Clause 52.232-25, Prompt  Payment.    g. Invoices shall be delivered electronically to the Contracting Officer (CO), the Contracting  Officer’s Representative (COR), PSC, and e-Room electronically. Unless otherwise specified by  the Contracting Officer, all deliverables, invoices, and reports furnished to the Government  under the resultant contract shall be addressed as follows:      [**]  Contracting Officer  HHS/ASPR/AMCG  200 C Street, S.W.  Washington, DC 20024  Email: [**]  [**]  Contracting Officer Representative  HHS/ASPR/BARDA  200 C Street, S.W.  Washington, DC 20024  Email: [**]  Email invoices to:   PSC_Invoices@psc.hhs.gov  e-Room      ARTICLE G.5.  INDIRECT COST RATES    The established provisional billing rates are based on rates approved by NIH-DFAS and adjustments  made for consumable materials, which are specific to this contract HHSO100201600030C, per 2016  Provisional Billing Rate letter dated September 15, 2016. The following interim provisional indirect  rates will be utilized for billing purposes during the period of performance: Fringe benefits at [**]%,  Development O/H at [**]%, G&A at [**]% and Material and Subcontracting Handling at [**]%. Final  rate proposals must be sent to the Contracting Officer upon immediate notification from the cognizant  audit agency. See FAR Clause 52.216-7, Allowable Cost and Payment.    ARTICLE G.6.  PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS  SUBCONTRACTORS, FAR 52.232-40 (December 2013)    (a) Upon receipt of accelerated payments from the Government, the Contractor shall make  accelerated payments to its small business subcontractors under this contract, to the maximum  extent practicable and prior to when such payment is otherwise required under the applicable  contract or subcontract, after receipt of a proper invoice and all other required documentation  from the small business subcontractor.    (b) The acceleration of payments under this clause does not provide any new rights under the  prompt Payment Act.    (c) Include the substance of this clause, include this paragraph c, in all subcontracts with small  business concerns, including subcontracts with small business concerns for the acquisition of  commercial items.    ARTICLE G.7.  POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE    1. Contractor Performance Evaluations    Interim and final evaluations of Contractor performance will be prepared on this contract in  accordance with FAR Subpart 42.15. The final performance evaluation will be prepared at the time of  completion of work. In addition to the final evaluation, interim evaluation(s) will be prepared annually  as to coincide with the Anniversary date of the contract.    Interim and final evaluations will be provided to the Contractor as soon as practicable after  completion of the evaluation. The Contractor will be permitted thirty days to review the document and  to submit additional information or a rebutting statement. If agreement cannot  

 

  25   be reached between the parties, the matter will be referred to an individual one level above the Contracting Officer  whose decision will be final.    Copies of the evaluations, Contractor responses, and review comments, if any, will be retained as part of the  contract file, and may be used to support future award decisions.    2. Electronic Access to Contractor Performance Evaluations    Contractors may access evaluations through a secure website for review and comment at the following:    http://cpars.gov    ARTICLE G.8.  CONTRACT COMMUNICATIONS/CORRESPONDENCE    The Contractor shall identify all correspondence, reports, and other data pertinent to this contract by imprinting the  contract number HHSO100201600030C from Page 1 of the contract.    ARTICLE G.9.  GOVERNMENT PROPERTY    1. In addition to the requirements of the clause, GOVERNMENT PROPERTY, incorporated in SECTION I of this  contract, the Contractor shall comply with the provisions of HHS Publication, "Contractor's Guide for Control of  Government Property," which is incorporated into this contract by reference. This document can be accessed at:    http://www.hhs.gov/hhsmanuals/ (HHS Logistics Management Manual)    Among other issues, this publication provides a summary of the Contractor's responsibilities regarding purchasing  authorizations and inventory and reporting requirements under the contract.    2. Notwithstanding the provisions outlined in the HHS Publication, "Contractor's Guide for Control of Government  Property," which is incorporated in this contract in paragraph 1 above, the Contractor shall use the form entitled,  "Report of Government Owned, Contractor Held Property" for submitting summary reports required under this  contract, as directed by the Contracting Officer or his/her designee. This form is included as an attachment in  SECTION J of this contract.    3. Title will vest in the Government for equipment purchased as a direct cost.  

 

  26   Section H – Special Contract Requirements    ARTICLE H.1. PROTECTION OF HUMAN SUBJECTS    a. The Contractor agrees that the rights and welfare of human subjects involved in research under this contract shall  be protected in accordance with 45 CFR Part 46 and with the Contractor's current Assurance of Compliance on file  with the Office for Human Research Protections (OHRP), Department of Health and Human Services. The  Contractor further agrees to provide certification at least annually that the Institutional Review Board has reviewed  and approved the procedures, which involve human subjects in accordance with 45 CFR Part 46 and the  Assurance of Compliance.    b. The Contractor shall bear full responsibility for the performance of all work and services involving the use of human  subjects under this contract and shall ensure that work is conducted in a proper manner and as safely as is feasible.  The parties hereto agree that the Contractor retains the right to control and direct the performance of all work under  this contract. The Contractor shall not deem anything in this contract to constitute the Contractor or any  subcontractor, agent or employee of the Contractor, or any other person, organization, institution, or group of any  kind whatsoever, as the agent or employee of the Government. The Contractor agrees that it has entered into this  contract and will discharge its obligations, duties, and undertakings and the work pursuant thereto, whether  requiring professional judgment or otherwise, as an independent Contractor without imputing liability on the part of  the Government for the acts of the Contractor or its employees.    c. Contractors involving other agencies or institutions in activities considered to be engaged in research involving  human subjects must ensure that such other agencies or institutions obtain their own FWA if they are routinely  engaged in research involving human subjects or ensure that such agencies or institutions are covered by the  Contractors’ FWA via designation as agents of the institution or via individual investigator agreements (see OHRP  website at: http://www.hhs.gov/ohrp/policy/guidanceonalternativetofwa.pdf).    d. If at any time during the performance of this contract, the Contracting Officer determines, in consultation with OHRP  that the Contractor is not in compliance with any of the requirements and/or standards stated in paragraphs (a) and  (b) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under  this contract until the Contractor corrects the noncompliance. The Contracting Officer may communicate the notice  of suspension by telephone with confirmation in writing. If the Contractor fails to complete corrective action within  the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may,  after consultation with OHRP, terminate this contract in whole or in part, and the Contractor's name may be  removed from the list of those Contractors with approved Human Subject Assurances.    ARTICLE H.2. NON-CLINICAL RESEARCH    PHS Policy on Humane Care and Use of Laboratory Animals    Before initiation of research and then with the annual progress report, the Contractor must submit to the Government a  copy of the current Institutional Animal Care and Use Committees (IACUC) documentation of continuing review and  approval and the Office of Laboratory Animal Welfare (OLAW- National Institutes of Health) Federal Wide Assurance  (FWA) number for the institution or site.  If other institutions are involved in the research (e.g., a multicenter trial or study), each institution's IACUC must review  and approve the protocol. They must also provide the Government initial documentation and documentation of  continuing review and approval and FWA number.  

 

  27   The Contractor must ensure that the applications as well as all protocols are reviewed by the performing institution’s  IACUC.  To help ensure the safety of animals used in BARDA funded studies, the Contractor must provide the Government  copies of documents related to all major changes in the status of ongoing protocols, including the following:  a) All amendments or changes to the protocol, identified by protocol version number, date,  or both and date it is valid.  b) All material changes in IACUC policies and procedures, identified by version number, date,  and all required signatories (if applicable)  c) Termination or temporary suspension of the study(ies) for regulatory issues  d) Termination or temporary suspension of the protocol.  e) Any change that is made in the specific IACUC approval for the indicated study(ies).  f) Any other problems or issues that could affect the scientific integrity of the study(ies), i.e. fraud,  misrepresentation, misappropriation of funds, etc.  Contractors must notify the Government by email of any of the above changes within three business days from the time  Contractor becomes aware of such changes, followed by a letter signed by the institutional business official, detailing  notification of the change of status to the local IACUC and a copy of any responses from the IACUC.  If a non-clinical protocol has been reviewed by an institutional biosafety committee (IBC) or the NIH Recombinant DNA  Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval,  if any. See the NIH Guidelines for Research  Involving Recombinant DNA Molecules.    Non-Clinical Data and Safety Monitoring Requirements    The Contractor shall continue safety monitoring for all non-clinical studies of investigational drugs, devices, or  biologics. FDA expects non-clinical studies to include safety in addition to efficacy. The Contractor should consider  evaluation of clinical relevant safety markers in the pivotal and non-pivotal, non-clinical studies.  BARDA will work with the Contractors on decisions regarding the type and extent of safety data accrual to be employed  before the start of efficacy or safety studies.  The Contractor shall inform the Government of any upcoming site visits and/or audits of CRO facilities funded under  this effort. The Government reserves the right to accompany the Contractor on site visits and/or audits of CROs as the  Government deems necessary.    BARDA Review Process Before Non-Clinical Study Execution Begins    The Government is under the same policy-driven assurances as NIH in that it has a responsibility to ensure that  mechanisms and procedures are in place to protect the safety and welfare of animals used in BARDA funded non- clinical trials. Therefore, before study execution, the Contractor must provide the following (as applicable) for review  and approval by the Government:  1. Non-clinical research protocol to be submitted for IACUC approval identified by version number, date, or  both, including details of study design, euthanasia criteria, proposed interventions, and exclusion criteria.  Contractor should reduce the number of animals required for a study using power of statistics  2. Plans for the management of side effects, rules for interventions and euthanasia criteria  3. Procedures for assessing and collecting safety data  4. If a study is contracted through CRO(s), work orders and service agreements the Contractor shall assure  that an integrated safety documentation plan is in place for  

 

  28   the study site, pharmacy service records on the dosing material to be used and excipients, and laboratory  services (including histopathology).  5. Documentation that the Contractor or CRO and all staff responsible for the conduct of the research have  received required training in the protection and handling of animals  6. Purchasing of animals and/or other supplies for non-clinical studies funded in part or in whole by BARDA  requires written approval by the Contracting Officer. The Contractor must have the ability to return/re-sell  animals, at purchase price, to distributor or a third party, in the event that the protocols do not obtain  approval  7. Provide justification for whether studies require good laboratory practice (GLP) conditions    BARDA comments will be forwarded to the Contractor within two weeks (10 business days) of receipt of the above  information. The Contractor must address in writing all study design, safety, regulatory, ethical, and conflict of interest  concerns raised by the BARDA COR to the satisfaction of the Government before study execution. After the  Government receives the corrected documentation, a written protocol approval will be provided by the COR to the  Contractor. This written approval provides authorization to the Contractor to execute the specific non-clinical animal  study funded in part or in whole by the Government.    Documentation of IACUC approval, including OLAW FWA number, IACUC registration number, and IACUC name,  must be provided to the BARDA COR within 24 hours of receipt by the Contractor.    In case of problems or issues, the BARDA COR will contact the Contractor within two weeks (10 business days) by  email or fax, followed within 30 calendar days by an official letter to the principal investigator, with a copy to the  institution’s office of sponsored programs, listing issues and appropriate actions to be discussed.  Final decisions regarding ongoing safety reporting requirements for research not performed under an Investigational  New Drug Application (IND) must be made jointly by the Government and the Contractor.    ARTICLE H.3. CLINICAL RESEARCH    These Clinical Terms apply to all contracts that involve clinical research.    The Government shall have unlimited rights to all protocols, data generated from the execution of these protocols, and  final reports, funded by the Government under this contract, as defined in Rights in Data Clause in FAR 52.227-14. The  Government reserves the right to request that the Contractor provide any contract deliverable in a non-proprietary form,  to ensure the Government has the ability to review and distribute the deliverables, as the Government deems  necessary.    H.3.1 Safety and Monitoring Issues    Institutional Review Board (IRB) or Independent Ethics Committee (IEC) Approval  Before initiation of research and then with Annual Progress Reports, the Contractor shall submit to the Government a  copy of the current IRB or IEC approved informed consent document, documentation of continuing review and  approval and the Office of Human Research Protections (OHRP) FWA number for the institution or site.    If other institutions are involved in the research (e.g., a multicenter clinical trial or study), each institution's IRB or IEC  must review and approve the protocol. They must also provide the Government initial and annual documentation of  continuing review and approval, including the current approved informed consent document and FWA number.    The grantee institution must ensure that the applications as well as all protocols are reviewed by their IRB or IEC.    To help ensure the safety of participants enrolled in BARDA-funded studies, the Contractor must provide the  Government a summary explanation and copies of documents related to all major changes in the status of ongoing  protocols, including the following:  

 

  29   1. All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is  valid.  2. All changes in informed consent documents, identified by version number, date, or both and dates it is valid.  3. Termination or temporary suspension of patient accrual.  4. Termination or temporary suspension of the protocol.  5. Any change in IRB approval.  6. Any other problems or issues that could affect the participants in the studies.    Contractors must notify BARDA through the Contracting Officer’s Representative (COR) and Contracting Officer (CO)  of any of the above changes within 24 hours from the time the Contractor becomes aware of the change by email,  followed by a letter signed by the institutional business official, detailing notification of the change of status to the local  IRB and a copy of any responses from the IRB or IEC.    If a clinical protocol has been reviewed by an Institutional Bio-safety Committee (IBC) or the NIH Recombinant DNA  Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval,  if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.    H.3.2. Data and Safety Monitoring Requirements    The Contractor may be required to conduct independent safety monitoring for clinical trials of investigational drugs,  devices, or biologics; clinical trials of licensed products; and clinical research of any type involving more than minimal  risk to volunteers. Independent monitoring can take         a variety of forms. Phase III clinical trials must have an  assigned independent data and         safety monitoring board (DSMB); other trials may require DSMB oversight as well.  The Contractor shall inform the Government of any upcoming site visits and/or audits of Contractor facilities funded  under this effort. BARDA reserves the right to accompany the Contractor on site visits and/or audits of Contractors and  Subcontractors as the Government deems necessary.  The type of monitoring to be used shall be mutually agreed upon between the Contractor and the Government before  enrollment starts. Discussions with the responsible BARDA COR regarding appropriate safety monitoring and approval  of the final monitoring plan by BARDA must occur before patient enrollment begins and may include discussions about  the appointment of one of the following:    1. Independent Safety Monitor – a physician or other appropriate expert who is independent of the study  and available in real time to review and recommend appropriate action regarding adverse events and other  safety issues.    2. Independent Monitoring Committee (IMC) or Safety Monitoring Committee (SMC) – a small group of  independent investigators and biostatisticians who review data from a particular study.    3. Data and Safety Monitoring Board – an independent committee charged with reviewing safety and trial  progress and providing advice with respect to study continuation, modification, and termination. The  Contractor may be required to use an established BARDA DSMB or to organize an independent DSMB. All  phase III clinical trials must be reviewed by a DSMB; other trials may require DSMB oversight as well. Please  refer to: NIAID Principles for Use of a Data and Safety Monitoring Board (DSMB) For Oversight of Clinical  Trials Policy. The Government retains the right to place a nonvoting member on the DSMB.    When a monitor or monitoring board is organized, a description of it, its charter or operating procedures (including a  proposed meeting schedule and plan for review of adverse events), and roster and curriculum vitae from all members  must be submitted to and approved by the Government before enrollment starts.    Additionally, the Contractor must submit written summaries of all reviews conducted by the monitoring group to the  Government within 30 days of reviews or meetings.  

 

  30   H.3.3. BARDA Protocol Review Process Before Patient Enrollment Begins    BARDA has a responsibility to ensure that mechanisms and procedures are in place to protect the safety of  participants in BARDA-supported clinical trials. Therefore, before patient accrual or participant enrollment, the  Contractor must provide the following (as applicable) for review and approval by the Government:    1. Clinical research protocol to be submitted for approval by the IRB or IEC, identified by version number,  date, or both, including details of study design, proposed interventions, patient eligibility, and exclusion criteria;  2. Informed consent document, identified by version number, date, or both and date it is valid;  3. Plans for the management of side effects;  4. Procedures for assessing and reporting adverse events;  5. Plans for data and safety monitoring (see B above) and monitoring of the clinical study site, pharmacy, and  laboratory;  6. Documentation that the Contractor and all study staff responsible for the design or conduct of the  research have received Good Clinical Practice (GCP) training in the protection of human subjects.    BARDA comments will be forwarded to the Contractor within two weeks (10 business days) of receipt of the above  information. The Contractor must address in writing all study design, safety, regulatory, ethical, and conflict of interest  concerns raised by the BARDA COR to the satisfaction of the Government before patient accrual or participant  enrollment can begin. After the Government receives the corrected documentation, a written protocol approval will be  provided by the COR and CO to the Contractor. This written approval provides authorization to the Contractor to  execute the specific clinical study funded in part or in whole by the Government.    Documentation of IRB or IEC approval, including OHRP FWA number, IRB or IEC registration number, and IRB and  IEC name, must be provided to the BARDA COR within 24 hours of receipt by the Contractor.    H.3.4. Required Time-Sensitive Notification    Under an IND or IDE, the sponsor must provide FDA safety reports of serious adverse events. Under these Clinical  Terms of Award, the Contractor must submit copies to the responsible BARDA Contracting Officer's representative  (COR) as follows:    1. Expedited safety report of unexpected or life-threatening experience or death – A copy of any report of  unexpected or life-threatening experience or death associated with the use of an IND drug, which must be  reported to FDA by telephone or fax as soon as possible but no later than seven days after the IND sponsor’s  receipt of the information, must be submitted to the BARDA program officer or the Contracting Officer's  Representative within 24 hours of FDA notification.    2. Expedited safety reports of serious and unexpected adverse experiences – A copy of any report of unexpected  and serious adverse experience associated with use of an IND drug or any finding from tests in laboratory  animals that suggests a significant risk for human subjects, which must be reported in writing to FDA as soon  as possible but no later than 15 calendar days after the IND sponsor’s receipt of the information, must be  submitted to the BARDA Contracting Officer’s Representative within 24 hours of FDA notification.      3. IDE reports of unanticipated adverse device effect – A copy of any reports of unanticipated adverse device  effect submitted to FDA must be submitted to the BARDA Contracting Officer’s Representative within 24 hours  of FDA notification.    4. Expedited safety reports – shall be sent to the BARDA COR concurrently with the report to FDA.  

 

  31   5. Other adverse events documented during the course of the trial shall be included in the annual IND report  and reported to the BARDA annually.    In case of problems or issues, the BARDA COR will contact the Contractor within 10 working days by email, followed  within 7 calendar days by an official letter to the Contractor. The Contractor shall forward the official letter to the  principal investigator listing issues and appropriate actions to be discussed.    Safety reporting for research not performed under an IND.    Ongoing safety reporting requirements for research not performed under an IND shall be mutually agreed upon by the  BARDA Contracting Officer’s Representative and the Contractor.    ARTICLE H.4. HUMAN MATERIALS    The acquisition and supply of all human specimen material (including fetal material) used under this contract shall be  obtained by the Contractor in full compliance with applicable State and Local laws and the provisions of the Uniform  Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise, will be offered to any  person to influence their donation of human material.    ARTICLE H.5. CARE OF LIVE VERTEBRATE ANIMALS    a. Before undertaking performance of any contract involving animal-related activities where the species is  regulated by USDA, the Contractor shall register with the Secretary of Agriculture of the United States in  accordance with 7 U.S.C. 2136 and 9 CFR sections 2.25 through 2.28. The Contractor shall furnish  evidence of the registration to the Contracting Officer.    b. The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of  Agriculture under 7 U.S.C. 2133 and 9 CFR Sections 2.1- 2.11, or from a source that is exempt from licensing  under those sections.    c. The Contractor agrees that the care, use and intended use of any live vertebrate animals in the performance  of this contract shall conform with the Public Health Service (PHS) Policy on Humane Care of Use of  Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for the Care  and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and  regulations of the United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR Subchapter  A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern.    d. If at any time during performance of this contract, the Contracting Officer determines, in consultation with the  Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is not in  compliance with any of the requirements and standards stated in paragraphs (a) through (c) above, the  Contracting Officer may immediately suspend, in whole or in part, work and further payments under this  contract until the Contractor corrects the noncompliance. Notice of the suspension may be communicated by  telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time  designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, in  consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor's name may be  removed from the list of those contractors with approved Assurances.    Note: The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional  Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility  is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program  may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737  (E-mail: ace@aphis.usda.gov; W eb site: (http://www.aphis.usda.gov/animal_welfare).  

 

  32   ARTICLE H.6. ANIMAL WELFARE    All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service  Policy on Humane Care and Use of Laboratory Animals. This policy may be accessed  at:http://grants1.nih.gov/grants/olaw/references/phspol.htm    ARTICLE H.7. INFORMATION ON COMPLIANCE WITH ANIMAL CARE REQUIREMENTS    Registration with the U. S. Dept. of Agriculture (USDA) is required to use regulated species of animals for biomedical  purposes. USDA is responsible for the enforcement of the Animal Welfare Act (7 U.S.C. 2131 et. seq.),  http://www.nal.usda.gov/awic/legislat/awa.htm.    The Public Health Service (PHS) Policy is administered by the Office of Laboratory Animal Welfare (OLAW)  http://grants2.nih.gov/grants/olaw/olaw.htm. An essential requirement of the PHS Policy  http://grants2.nih.gov/grants/olaw/references/phspol.htm is that every institution using live vertebrate animals must  obtain an approved assurance from OLAW before they can receive funding from any component of the U. S. Public  Health Service.    The PHS Policy requires that Assured institutions base their programs of animal care and use on the Guide for the  Care and Use of Laboratory Animals  http://www.nap.edu/readingroom/books/labrats/ and that they comply with the  regulations (9 CFR, Subchapter A)http://www.nal.usda.gov/awic/legislat/usdaleg1.htm  issued by the U.S.   Department  of Agriculture (USDA) under the Animal Welfare Act. The Guide may differ from USDA regulations in some respects.  Compliance with the USDA regulations is an absolute requirement of this Policy.    The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)  http://www.aaalac.org is a professional organization that inspects and evaluates programs of animal care for institutions  at their request. Those that meet the high standards are given the accredited status. As of the 2002 revision of the  PHS Policy, the only accrediting body recognized by PHS is the AAALAC. While AAALAC Accreditation is not required  to conduct biomedical research, it is highly desirable. AAALAC uses the Guide as their primary evaluation tool. They  also use the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. It is published  by the Federated of Animal Science Societies  http://www.fass.org.    ARTICLE H.8. REQUIREMENTS FOR ADEQUATE ASSURANCE OF PROTECTION OF VERTEBRATE  ANIMAL SUBJECTS    The PHS Policy on Humane Care and Use of Laboratory Animals requires that applicant organizations proposing to  use vertebrate animals file a written Animal Welfare Assurance with the Office for Laboratory Animal Welfare  (OLAW), establishing appropriate policies and procedures to ensure the humane care and use of live vertebrate  animals involved in research activities supported by the PHS. The PHS Policy stipulates that an applicant  organization, whether domestic or foreign, bears responsibility for the humane care and use                       of  animals in PHS- supported research activities. Also, the PHS policy defines “animal” as “any live, vertebrate animal  used, or intended for use, in research, research training, experimentation, biological testing or for related purposes.”  This Policy implements and supplements the U.S. Government Principles for the Utilization and Care of Vertebrate  Animals Used in Testing, Research, and Training, and requires that institutions use the Guide for the Care and Use  of Laboratory Animals as a basis for developing and implementing an institutional animal care and use program.  This Policy does not affect applicable State or   local laws or regulations that impose more stringent standards for the  care and use of laboratory animals. All institutions are required to comply, as applicable, with the Animal Welfare  Act as amended (7 USC 2131 et. seq.) and other Federal statutes and regulations relating to animals. These  documents are available from the Office of Laboratory Animal  Welfare, National Institutes of Health, Bethesda, MD 20892, (301) 496-7163. See   http://grants.nih.gov/grants/olaw/olaw.htm.    No PHS supported work for research involving vertebrate animals will be conducted by an organization, unless that  organization is operating in accordance with an approved Animal  

 

  33   Welfare Assurance and provides verification that the Institutional Animal Care and Use Committee (IACUC) has  reviewed and approved the proposed activity in accordance with the PHS policy. Applications may be referred by the  PHS back to the institution for further review in the case of apparent or potential violations of the PHS Policy. No  award to an individual will be made unless that individual is affiliated with an assured organization that accepts  responsibility for compliance with the PHS Policy. Foreign applicant organizations applying for PHS awards for  activities involving vertebrate animals are required to comply with PHS Policy or provide evidence that acceptable  standards for the humane care and use of animals will be met.  Foreign applicant organizations are not required to submit IACUC approval, but should provide information that is  satisfactory to the Government to provide assurances for the humane care  of such animals.    ARTICLE H.9. APPROVAL OF REQUIRED ASSURANCE BY OLAW    Under governing regulations, federal funds which are administered by the Department of Health and Human  Services, Office of Biomedical Advanced Research and Development Authority (BARDA) shall not be expended by  the Contractor for research involving live vertebrate animals, nor shall live vertebrate animals be involved in research  activities by the Contractor under this award unless a satisfactory assurance of compliance with 7 U.S.C. 2316 and 9  CFR Sections 2.25-2.28 is submitted within 30 days of the initiation of research and approved by the Office of  Laboratory Animal Welfare (OLAW). Each performance site (if any) must also assure compliance with 7 U.S.C. 2316  and 9 CFR Sections 2.25-2.28 with the following restriction: Only activities which do not directly involve live  vertebrate animals (i.e. are clearly severable and independent from those activities that do involve live vertebrate  animals) may be conducted by the Contractor or individual performance sites pending OLAW approval of their  respective assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28. Additional information  regarding OLAW may be obtained via the Internet at  http://grants2.nih.gov/grants/olaw/references/phspol.htm    ARTICLE H.10.  NEEDLE EXCHANGE    The Contractor shall not use contract funds to carry out any program of distributing sterile needles or syringes for the  hypodermic injection of any illegal drug.    ARTICLE H.11.  ACKNOWLEDGEMENT OF FEDERAL FUNDING    The Contractor shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations  and other documents describing projects or programs funded in whole or in part with Federal money: (1) the  percentage of the total costs of the program or project which will be financed with Federal money; (2) the dollar amount  of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or  program that will be financed by nongovernmental sources.    ARTICLE H.12.  CONTINUED  BAN ON FUNDING ABORTION AND CONTINUED BAN OF FUNDING OF HUMAN  EMBRYO RESEARCH    a. The Contractor shall not use any funds obligated under this contract for any abortion.    b. The Contractor shall not use any funds obligated under this contract for the  following:  1. The creation of a human embryo or embryos for research purposes; or    2. Research in which a human embryo or embryos are destroyed,  discarded, or knowingly subjected to risk of injury of death greater than that allowed for research  on fetuses in utero under 45 CFR part 46 and Section 498(b) of the Public Health Service Act (42  U.S.C. 289g(b)).    c. The term “human embryo or embryos'” includes any organism,  not protected as a human subject under 45 CFR part 46 as of the date  

 

  34    of the enactment of this Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from  one or more human gametes of human diploid cells.    d. The Contractor shall not use any Federal funds for the cloning of human beings.    ARTICLE H.13. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION    The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading.    ARTICLE H.14. OMB CLEARANCE    In accordance with HHSAR 352.211-3, Paperwork Reduction Act, the Contractor shall not proceed with surveys or  interviews until such time as Office of Management and Budget (OMB) Clearance for conducting interviews has been  obtained by the Contracting Officer's Representative (COR) and the Contracting Officer has issued written approval to  proceed.    ARTICLE H.15.  RESEARCH INVOLVING HUMAN FETAL TISSUE    All research involving human fetal tissue shall be conducted in accordance with the Public Health Service Act, 42 U.S.C.  289g-1 and 289g-2. Implementing regulations and guidance for conducting research on human fetal tissue may be  found at 45 CFR 46, Subpart B and  http://grants1.nih.gov/grants/guide/notice-files/not93-235.html and any subsequent  revisions to this NIH Guide to Grants and Contracts ("Guide") Notice.    The Contractor shall make available, for audit by the Secretary, HHS, the physician statements and informed consents  required by 42 USC 289g-1(b) and (c), or ensure HHS access to those records, if maintained by an entity other than  the Contractor.    ARTICLE H.16. REPORTING MATTERS INVOLVING FRAUD, WASTE, AND ABUSE    Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in BARDA funded  programs is encouraged to report such matters to the HHS Inspector General's Office in writing or on the Inspector  General's Hotline. The toll free number is 1-800-HHS-TIPS  (1-800-447-8477). All telephone calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov  and the  mailing address is:    Office of Inspector General  Department of Health and Human Services TIPS HOTLINE  P.O. Box 23489 Washington, D.C. 20026    ARTICLE H.17.  PROHIBITION ON CONTRACTOR INVOLVEMENT WITH TERRORIST ACTIVITIES    The Contractor acknowledges that U.S. Executive Orders and Laws, including but not limited to  E.O. 13224 and P.L. 107-56, prohibit transactions with, and the provision of resources and support to, individuals and  organizations associated with terrorism. It is the legal responsibility of the Contractor to ensure compliance with these  Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.    ARTICLE H.18. RESTRICTION ON PORNOGRAPHY ON COMPUTER NETWORKS  The Contractor shall not use contract funds to maintain or establish a computer network unless such network blocks  the viewing, downloading, and exchanging of pornography.    ARTICLE H.19. CERTIFICATION OF FILING AND PAYMENT OF TAXES  The Contractor must be in compliance with Section 518 of the Consolidated Appropriations Act of FY 2014.  

 

  35   ARTICLE H.20. ELECTRONIC INFORMATION AND TECHNOLOGY ACCESSIBILITY NOTICE    a. Section 508 of the Rehabilitation Act of 1973 (29 U.S.C. 794d), as amended by the Workforce Investment Act of  1998 and the Architectural and Transportation Barriers Compliance Board Electronic and Information (EIT)  Accessibility Standards (36 CFR part 1194), require that when Federal agencies develop, procure, maintain, or  use electronic and information technology, Federal employees with disabilities have access to and use of  information and data that is comparable to the access and use by Federal employees who are not individuals  with disabilities, unless an undue burden would be imposed on  the agency. Section 508 also requires that  individuals with disabilities, who are members of the public seeking information or services from a Federal  agency, have access to and use of information and data that is comparable to that provided to the public who  are not individuals with disabilities, unless an undue burden would be imposed on the agency.    b. Accordingly, any Offeror responding to this solicitation must comply with established HHS EIT accessibility  standards. Information about Section 508 is available at  http://www.hhs.gov/web/508. The complete text of the  Section 508 Final Provisions can be accessed at http://www.access-board.gov/sec508/standards.htm.    c. The Section 508 accessibility standards applicable to this solicitation are stated in the clause at 352.239-74,  Electronic and Information Technology Accessibility.    In order to facilitate the Government's determination whether proposed EIT supplies meet applicable Section  508 accessibility standards, Offerors must submit an HHS Section 508 Product Assessment Template, in  accordance with its completion instructions. The purpose of the template is to assist HHS acquisition and  program officials in determining whether proposed EIT supplies conform to applicable Section 508 accessibility   standards. The template allows Offerors or developers to self-evaluate their supplies and document--in detail-- whether they conform to a specific Section 508 accessibility standard, and any underway remediation efforts  addressing conformance issues.  Instructions for preparing the HHS Section 508 Evaluation Template are available under Section 508 policy on  the HHS Web site http://hhs.gov/web/508.    In order to facilitate the Government's determination whether proposed EIT services meet applicable Section  508 accessibility standards, Offerors must provide enough information to assist the Government in determining  that the EIT services conform to Section 508 accessibility standards, including any underway remediation efforts  addressing conformance issues.    d. Respondents to this solicitation must identify any exception to Section 508 requirements. If a Offeror claims its  supplies or services meet applicable Section 508 accessibility standards, and it is later determined by the  Government, i.e., after award of a contract or order, that supplies or services delivered do not conform to the  described accessibility standards, remediation of the supplies or services to the level of conformance specified  in the contract will be the responsibility of the Contractor at its expense.    (End of provision)    ARTICLE H.21.  FULL EARNED VALUE MANAGEMENT SYSTEM    a. The Contractor shall use an Earned Value Management System (EVMS) that is compliant with the guidelines in  ANSI/EIA Standard-748 (current version at the time of award) to manage this contract. If the Contractor's  current EVMS is not compliant at the time of award, see paragraph (b) of this clause. The Contractor shall  submit EVM reports in accordance with the requirements of this contract.    b. If, at the time of award, the Contractor's EVM system is not in compliance with the EVMS guidelines in  ANSI/EIA Standard-748 (current version at time of award), the Contractor shall:  

 

  36   a. Apply the current system to the contract; and  b. Take necessary and timely actions to meet the milestones in the Contractor's EVMS plan approved  by the Contracting Officer.    c. HHS will not formally validate or accept the Contractor's EVMS with respect to this contract. The use of the  Contractor's EVMS for this contract does not imply HHS acceptance of the Contractor's EVMS for application  to future contracts. The Contracting Officer or designee will conduct a Compliance Review to assess the  Contractor's compliance with its approved plan. If the Contractor does not follow the approved implementation  schedule or correct all resulting system deficiencies noted during the Compliance Review within a reasonable  time, the Contracting Officer may take remedial action that may include, but is not limited to, suspension of or  reduction in progress payments, or a reduction in fee.    d. HHS will conduct a Performance Measurement Baseline Review (PMBR). If a pre-award PMBR has not been  conducted, a post-award PMBR will be conducted by HHS as early as practicable, but no later than ninety (90)  days after contract award. The Contracting Officer may also require a PMBR as part of the exercise of an  option or the incorporation of a major modification.    e. Unless a waiver is granted by the CFA, Contractor-proposed EVMS changes require approval of the CFA prior  to implementation. The CFA will advise the Contractor of the acceptability of such changes within 30 calendar  days after receipt of the notice of proposed changes from the Contractor. If the advance approval requirements  are waived by the CFA, the Contractor shall disclose EVMS changes to the CFA at least 14 calendar days  prior to the effective date of implementation.    f. Unless a waiver is granted by the CFA, Contractor-proposed EVMS changes require approval of the CFA prior  to implementation. The CFA will advise the Contractor of the acceptability of such changes within 30 calendar  days after receipt of the notice of proposed changes from the Contractor. If the advance approval requirements  are waived by the CFA, the Contractor shall disclose EVMS changes to the CFA at least 14 calendar days  prior to the effective date of implementation.    g. The Contractor shall provide access to all pertinent records and data requested by the Contracting Officer or a  duly authorized representative as necessary to permit Government surveillance to ensure that the EVMS  conforms, and continues to conform to the requirements referenced in paragraph (a) of this clause.    ARTICLE H.22.  CONFIDENTIALITY OF INFORMATION    a. Confidential information, as used in this article, means information or data of a personal nature about an  individual, or proprietary information or data submitted by or pertaining to an institution or organization.    b. The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific  information and/or categories of information which the Government will furnish to the Contractor or that the  Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor  may, by mutual consent, identify such confidential information from time to time during the performance of the  contract. Failure to agree will be settled pursuant to the "Disputes" clause.    c. If it is established elsewhere in this contract that information to be utilized under this contract, or a portion  thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in  the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of  records determined to be subject to the Privacy Act.    d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior  written consent of the individual, institution, or organization.  

 

  37   e. Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the  material in question is subject to the Privacy Act or is confidential information subject to the provisions of this  article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release,  disclosure, dissemination, or publication.    f. Contracting Officer determinations will reflect the result of internal coordination with appropriate program  and legal officials.    g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other  Federal, State or local laws.    ARTICLE H.23.  INSTITUTIONAL RESPONSIBILITY REGARDING INVESTIGATOR FINANCIAL CONFLICTS OF  INTERESTS    The Institution (includes any Contractor, public or private, excluding a Federal agency) shall comply with the  requirements of 45 CFR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by  establishing standards to ensure that Investigators (defined as the project director or principal Investigator and any  other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded  under BARDA contracts, or proposed for such funding, which may include, for example, collaborators or consultants)  will not be biased by any Investigator financial conflicts of interest. 45 CFR Part 94  is available at the following Web  site: http://www.ecfr.gov/cgi-bin/text-   idx?c=ecfr&SID=0af84ca649a74846f102aaf664da1623&rgn=div5&view=text&node=45:1.0.1.1.51  &idno=45    As required by 45 CFR Part 94, the Institution shall, at a minimum:    a. Maintain an up-to-date, written, enforceable policy on financial conflicts of interest that complies with 45 CFR  Part 94, inform each Investigator of the policy, the Investigator's reporting responsibilities regarding disclosure  of significant financial interests, and the applicable regulation, and make such policy available via a publicly  accessible Web site, or if none currently exist, available to any requestor within five business days of a  request. A significant financial interest means a financial interest consisting of one or more of the following  interests of the Investigator (and those of the Investigator's spouse and dependent children) that reasonably  appears to be related to the Investigator's institutional responsibilities:    1. With regard to any publicly traded entity, a significant financial interest exists if the value of any  remuneration received from the entity in the twelve months preceding the disclosure and the value of  any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000.  Included are payments and equity interests;  2. With regard to any non-publicly traded entity, a significant financial interest exists if the value of any  remuneration received from the entity in the twelve months preceding the disclosure, when  aggregated, exceeds $5,000, or when the Investigator (or the Investigator's spouse or dependent  children) holds any equity interest; or  3. Intellectual property rights and interests, upon receipt of income related to such rights and interest.    Significant financial interests do not include the following:    1. Income from seminars, lectures, or teaching, and service on advisory or review panels for  government agencies, Institutions of higher education, academic teaching hospitals, medical centers,  or research institutes with an Institution of higher learning; and  2. Income from investment vehicles, such as mutual funds and retirement accounts, as long as the  Investigator does not directly control the investment decisions  

 

  38   made in these vehicles.    b. Require each Investigator to complete training regarding the Institution's financial conflicts of interest policy  prior to engaging in research related to any BARDA funded contract and at least every four years. The  Institution must take reasonable steps [see Part 94.4(c)] to ensure that investigators working as  collaborators, consultants or subcontractors comply with the regulations.    c. Designate an official(s) to solicit and review disclosures of significant financial interests from each Investigator  who is planning to participate in, or is participating in, the BARDA funded research.    d. Require that each Investigator who is planning to participate in the BARDA funded research disclose to the  Institution's designated official(s) the Investigator's significant financial interest (and those of the Investigator's  spouse and dependent children) no later than the date of submission of the Institution's proposal for BARDA  funded research. Require that each Investigator who is participating in the BARDA funded research to submit  an updated disclosure of significant financial interests at least annually, in accordance with the specific time  period prescribed by the Institution during the period of the award as well as within thirty days of discovering or  acquiring a new significant financial interest.    e. Provide guidelines consistent with the regulations for the designated official(s) to determine whether an  Investigator's significant financial interest is related to BARDA funded research and, if so related, whether the  significant financial interest is a financial conflict of interest. An Investigator's significant financial interest is  related to BARDA funded research when the Institution, thorough its designated official(s), reasonably  determines that the significant financial interest: Could be affected by the BARDA funded research; or is in an  entity whose financial interest could be affected by the research. A financial conflict of interest exists when the  Institution, through its designated official(s), reasonably determines that the significant financial interest could  directly and significantly affect the design, conduct, or reporting of the BARDA funded research.    f. Take such actions as necessary to manage financial conflicts of interest, including any financial conflicts of a  subcontractor Investigator. Management of an identified financial conflict of interest requires development and  implementation of a management plan and, if necessary, a retrospective review and mitigation report pursuant  to Part 94.5(a).    g. Provide initial and ongoing FCOI reports to the Contracting Officer pursuant to Part 94.5(b).    h. Maintain records relating to all Investigator disclosures of financial interests and the Institution's review of, and  response to, such disclosures, and all actions under the Institution's policy or retrospective review, if applicable,  for at least 3 years from the date of final payment or, where applicable, for the other time periods specified in  48 CFR Part 4, subpart 4.7, Contract Records Retention.    i. Establish adequate enforcement mechanisms and provide for employee sanctions or other administrative  actions to ensure Investigator compliance as appropriate.    j. Complete the certification in Section K - Representations, Certifications, and Other Statements of Contractors  titled "Certification of Institutional Policy on Financial Conflicts of Interest".    If the failure of an Institution to comply with an Institution's financial conflicts of interest policy or a financial conflict  of interest management plan appears to have biased the design, conduct, or reporting of the BARDA funded  research, the Institution must promptly notify the Contracting Officer of the corrective action taken or to be taken.  The Contracting Officer will consider the situation and, as necessary, take appropriate action or refer the matter to  the Institution for further action, which may include directions to the Institution on how to maintain appropriate  objectivity in the BARDA funded research project.  

 

  39   The Contracting Officer and/or HHS may inquire at any time before, during, or after award into any Investigator  disclosure of financial interests, and the Institution's review of, and response to, such disclosure, regardless of  whether the disclosure resulted in the Institution's determination of a financial conflict of interests. The Contracting  Officer may require submission of the records or review them on site. On the basis of this review of records or  other information that may be available, the Contracting Officer may decide that a particular financial conflict of  interest will bias the objectivity of the BARDA funded research to such an extent that further corrective action is  needed or that the Institution has not managed the financial conflict of interest in accordance with Part 94.6(b).  The issuance of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved.    If the Contracting Officer determines that BARDA funded clinical research, whose purpose is to evaluate the safety  or effectiveness of a drug, medical device, or treatment, has been designed, conducted, or reported by an  Investigator with a financial conflict of interest that was not managed or reported by the Institution, the Institution  shall require the Investigator involved to disclose the financial conflict of interest in each public presentation of the  results of the research and to request an addendum to previously published presentations.    ARTICLE H.24. PUBLICATION AND PUBLICITY    The Contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant  Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever  publicizing the work under this contract in any media by including an acknowledgment substantially as follows:    "This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for  Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No.  HHSO100201600030C"    Press releases shall be considered to include the public release of information to any medium, excluding peer-reviewed  scientific publications. The Contractor shall ensure that the Contracting Officer's Representative (COR) has received an  advance copy of any press release related to this contract not less than five (5) working days prior to the issuance of the  press release.    ARTICLE H.25. ACCESS TO DOCUMENTATION/DATA    The Government shall have physical and electronic access to all documentation and data generated under this  contract, including: all data documenting Contractor performance, all data generated, all communications and  correspondence with regulatory agencies and bodies to include all audit observations, inspection reports, milestone  completion documents, and all Contractor commitments and responses. Contractor shall provide the Government with  an electronic copy of all correspondence with the FDA, within 5 business days of receipt. The Government shall  acquire unlimited rights to all data funded under a contract awarded in response to this RFP in accordance with FAR  Subpart 27.4 and FAR Clause 52.227-14.    ARTICLE H.26. DISSEMINATION OF INFORMATION    No information related to data obtained under this contract shall be released or publicized without the prior written  consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such  consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any  government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s)  securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining  regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or  other business transactions.  

 

  40    ARTICLE H.27.  DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION    The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading.    ARTICLE H.28.  IDENTIFICATION AND DISPOSITION OF DATA    The Contractor will be required to provide certain data generated under this contract to the Department of Health and  Human Services (HHS). HHS reserves the right to review any other data determined by HHS to be relevant to this  contract. The Contractor shall keep copies of all data required by the Food and Drug Administration (FDA) relevant to  this contract for the time specified by the FDA.    ARTICLE H.29.  CONFLICT OF INTEREST    The Contractor represents and warrants that, to the best of the Contractor's knowledge and belief, there are no relevant  facts or circumstances which could give rise to an organizational         conflict of interest, as defined in FAR 2.101 and  Subpart 9.5, or that the Contractor has disclosed all such relevant information. Prior to commencement of any work, the  Contractor agrees to notify the Contracting Officer promptly that, to the best of its knowledge and belief, no actual or  potential conflict of interest exists or to identify to the Contracting Officer any actual or potential conflict of interest the  firm may have. In emergency situations, however, work may begin but notification shall be made within five (5) working  days. The Contractor agrees that if an actual or potential organizational conflict of interest is identified during  performance, the Contractor shall promptly make a full disclosure in writing to the Contracting Officer. This disclosure  shall include a description of actions which the Contractor has taken or proposes to take, after consultation with the  Contracting Officer, to avoid, mitigate, or neutralize the actual or potential conflict of interest. The Contractor shall  continue performance until notified by the Contracting Officer of any contrary action to be taken. Remedies include  termination of this contract for convenience, in whole or in part, if the Contracting Officer deems such termination  necessary to avoid an organizational conflict of interest. If the Contractor was aware of a potential organizational conflict  of interest prior to award or discovered an actual or potential conflict after award and did not disclose it or  misrepresented relevant information to the Contracting Officer, the Government may terminate the contract for default,  debar the Contractor from Government contracting, or pursue such other remedies as may be permitted by law or this  contract.    ARTICLE H.30.  IN-PROCESS REVIEW    In Process Reviews (IPR) will be conducted at the discretion of the Government to discuss the progression of the  milestones. The Government reserves the right to revise the milestones and budget pending the development of the  project. Deliverables may be required when the IPRs are conducted. The Contractor’s success in completing the  required tasks under each work segment must be demonstrated through the Deliverables and Milestones specified  under SECTION F. Those deliverables will constitute the basis for the Government’s decision, at its sole discretion, to  proceed with the work segment, or unilaterally institute changes to the work segment, or terminate the work segment.    IPRs may be scheduled at the discretion of the Government to discuss progression of the contract. The Contractor  shall provide a presentation following a prescribed template which will be provided by the Government at least 30  days prior to the IPR. The Contractor shall provide a draft presentation to the Contracting Officer at least 10 days prior  to the IPR.    ARTICLE H.31.  PRIVACY ACT APPLICABILITY    1) Notification is hereby given that the Contractor and its employees are subject to criminal penalties for violation of the  Privacy Act to the same extent as employees of the Government. The Contractor shall assure that each of its  employees knows the prescribed rules of conduct and that each is aware that he or she can be subjected to  criminal penalty for violation of the Act. A copy of 45 CFR Part 5b, Privacy Act Regulations, may be obtained at   http://www.gpoaccess.gov/cfr/index.html  

 

  41   2) The Project Officer/COR is hereby designated as the official who is responsible for monitoring Contractor  compliance with the Privacy Act.    3) The Contractor shall follow the Privacy Act guidance as contained in the Privacy Act System of Records number  09-25-0200. This document may be obtained at the following link:  http://oma.od.nih.gov/ms/privacy/pa- files/0200.htm    ARTICLE H.32.  QA AUDIT REPORTS    BARDA reserves the right to participate in QA audits. Upon completion of the audit/site visit the Contractor shall provide  a report capturing the findings, results and next steps in proceeding with the subcontractor. If action is requested of the  subcontractor, detailed concerns for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP  guidelines, as identified in the audit report, must be provided to BARDA. The Contractor shall provide responses from  the subcontractors to address these concerns and plans for corrective action execution.    • Contractor shall notify CO and COR of upcoming, ongoing, or recent audits/site visits of subcontractors as part  of weekly communications. The Contractor shall notify the CO and COR reasonably in advance of upcoming  QA audit so that Government personnel may participate in person at BARDA’s discretion.  • Contractor shall notify the COR and CO within 5 business days of report completion.    ARTICLE H.33.  BARDA AUDITS    Contractor shall accommodate periodic or ad hoc site visits by the Government. If the Government, the Contractor, or  other parties identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions,  and provide a report to the Government.    • If issues are identified during the audit, Contractor shall submit a report to the CO and COR detailing the  finding and corrective action(s) within 10 business days of the audit.  • COR and CO will review the report and provide a response to the Contractor with 10 business days.  • Once corrective action is completed, the Contractor will provide a final report to the CO and COR.    ARTICLE H.34.  SECURITY REPORTING REQUIREMENT    Violations of established security protocols shall be reported to the CO and COR upon discovery within 24 hours of its  receipt of any compromise, intrusion, loss or interference of its security processes and procedures. The Contractor  shall ensure that all software components that are not required for the operation and maintenance of the  database/control system has been removed and/or disabled. The Contractor shall provide to the CO and the COR  information appropriate     to Information and Information Technology software and service updates and/or workarounds       to mitigate all vulnerabilities associated with the data and shall maintain the required                level of system security.    The Contractor will investigate violations to determine the cause, extent, loss or compromise of sensitive program  information, and corrective actions taken to prevent future violations. The CO in coordination with BARDA will  determine the severity of the violation. Any contractual actions resulting from the violation will be determined by the  CO.  

 

  42   PART II - CONTRACT CLAUSES    SECTION I - CONTRACT CLAUSES    ARTICLE I.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)    This contract incorporates the following clauses by reference, with the same force and effect as if they were given in full  text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be  accessed electronically at these addresses:  https://www.acquisition.gov/FAR/ . HHSAR Clauses at:   http://www.hhs.gov/policies/hhsar/subpart352.html    .    General Clauses for Cost-Reimbursement/Fixed Price Research and Development Contract    (1) FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:    Reg Clause Date Clause Title  FAR 52.202-1 Nov 2013 Definitions  FAR 52.203-3 Apr 1984 Gratuities  FAR 52.203-5 May 2014 Covenant Against Contingent Fees  FAR 52.203-6 Sep 2006 Restrictions on Subcontractor Sales to the Government  FAR 52.203-7 May 2014 Anti-Kickback Procedures  FAR 52.203-8 May 2014 Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity  FAR 52.203-10 May 2014 Price or Fee Adjustment for Illegal or Improper Activity  FAR 52.203-12 Oct 2010 Limitation on Payments to Influence Certain Federal Transactions  FAR 52.203-13 Oct 2015 Contractor Code of Business Ethics and Conduct  FAR 52.203-14 Oct 2015 Display of Hotline Poster(s)  FAR 52.203-17 Apr 2014 Contractor Employee Whistleblower Rights and Requirement To Inform  Employees of Whistleblower Rights  FAR 52.204-4 May 2011 Printed or Copied Double-Sided on Postconsumer Fiber Content Paper  FAR 52.204-7 Jul 2013 System for Award Management  FAR 52.204-10 Oct 2015 Reporting Executive Compensation and First-Tier Subcontract Awards  FAR 52.204-13 Jul 2013 System for Award Management Maintenance  FAR 52.209-6 Oct 2015 Protecting the Government's Interests When Subcontracting With Contractors  Debarred, Suspended, or Proposed for Debarment  FAR 52.209-10 Nov 2015 Prohibition on Contracting with Inverted Domestic Corporations  FAR 52.210-1 Apr 2011 Market Research  FAR 52.215-2 Oct 2010 Audit and Records – Negotiation  FAR 52.215-8 Oct 1997 Order of Precedence - Uniform Contract Format  FAR 52.215-10 Aug 2011 Price Reduction for Defective Cost or Pricing Data  FAR 52.215-11 Aug 2011 Price Reduction for Defective Certified Cost or Pricing Data—Modifications.  FAR 52.215-12 Oct 2010 Subcontractor Certified Cost or Pricing Data  FAR 52.215-13 Oct 2010 Subcontractor Certified Cost or Pricing Data—Modifications  FAR 52.215-15 Oct 2010 Pension Adjustments and Asset Reversions  FAR 52.215-17 Oct 1997 Waiver of Facilities Capital Cost of Money  FAR 52.215-18 Jul 2005 Reversion or Adjustment of Plans for Postretirement Benefits (PRB) other than  Pensions  FAR 52.215-19 Oct 1997 Notification of Ownership Changes  FAR 52.215-21 Oct 2010 Requirements for Certified Cost or Pricing Data and Data Other Than Certified  Cost or Pricing Data -Modifications  FAR 52.215-23 Oct 2009 Limitations on Pass-Through Charges  FAR 52.216-7 Jun 2013 Allowable Cost and Payment  FAR 52.216-8 Jun 2011 Fixed Fee  FAR 52.219-8 Oct 2014 Utilization of Small Business Concerns  FAR 52.219-28 July 2013 Post-Award Small Business Program Representation  FAR 52.222-1 Feb 1997 Notice to the Government of Labor Disputes  FAR 52.222-2 Jul 1990 Payment for Overtime Premiums  

 

  43      FAR 52.222-3 Jun2003 Convict Labor  FAR 52.222-21 Apr 2015 Prohibition of Segregated Facilities  FAR 52.222-26 Apr 2015 Equal Opportunity  FAR 52.222-35 Oct 2015 Equal Opportunity for Veterans  FAR 52.222-36 Jul 2014 Equal Opportunity for Workers with Disabilities  FAR 52.222-37 Feb 2016 Employment Reports on Veterans  FAR 52.222-40 Dec 2010 Notification of Employee Rights Under the National Labor Relations Act  FAR 52.222-43 May 2014 Fair Labor Standards Act and Service Contract Labor Standards—Price  Adjustment (Multiple Year and Option Contracts)  FAR 52.222-50 Mar 2015 Combating Trafficking in Persons  FAR 52.222-54 Oct 2015 Employment Eligibility Verification  FAR 52.223-6 May 2001 Drug-Free Workplace  FAR 52.223-18 Aug 2011 Encouraging Contractor Policy to Ban Text Messaging While Driving  FAR 52.224-1 April 1984 Privacy Act Notification  FAR 52.224-2 April 1984 Privacy Act  FAR 52.225-13 Jun 2008 Restrictions on Certain Foreign Purchases  FAR 52.227-1 Dec 2007 Authorization and Consent, Alternate 1 (APR 1984)  FAR 52.227-2 Dec 2007 Notice and Assistance Regarding Patent and Copyright Infringement  FAR 52.227-3 Apr 1984 Patent Indemnity  FAR 52.227-11 May 2014 Patent Rights – Ownership by the Contractor  FAR 52.227-14 May 2014 Rights in Data - General  FAR 52.227-16 Jun 1987 Additional Data Requirements  FAR 52.228-7 Mar 1996 Insurance – Liability to Third Persons  FAR 52.229-3 Feb 2013 Federal, State and Local Taxes  FAR 52.230-2 Oct 2015 Cost Accounting Standards  FAR 52.230-6 June 2010 Administration of Cost Accounting Standards  FAR 52.232-1 Apr 1984 Payments  FAR 52.232-2 Apr 1984 Payments under Fixed-Price Research and Development Contracts  FAR 52.232-8 Feb 2002 Discounts for Prompt Payment  FAR 52.232-9 Apr 1984 Limitation on Withholding of Payments  FAR 52.232-11 Apr 1984 Extras  FAR 52.232-17 May 2014 Interest  FAR 52.232-20 Apr 1984 Limitation of Cost  FAR 52.232-23 May 2014 Assignment of Claims  FAR 52.232-25 Jul 2013 Prompt Payment  FAR 52.232-33 Jul 2013 Payment by Electronic Funds Transfer--System for Award Management  FAR 52.233-1 May 2014 Disputes  FAR 52.233-3 Aug 1996 Protest After Award, Alternate I  FAR 52.233-4 Oct 2004 Applicable Law for Breach of Contract Claim  FAR 52.242-1 Apr 1984 Notice of Intent to Disallow Costs  FAR 52.242-3 May 2014 Penalties for Unallowable Costs  FAR 52.242-4 Jan 1997 Certification of Final Indirect Costs  FAR 52.242-13 Jul 1995 Bankruptcy  FAR 52.243-1 Aug 1987 Changes - Fixed-Price Alternate V (Apr 1984).  FAR 52.243-2 Aug 1987 Changes—Cost-Reimbursement Alternate V (Apr 1984).  FAR 52.243.6 Apr 1984 Change Order Accounting  FAR 52.243-7 Apr 1984 Notification of Changes  FAR 52.244-2 Oct 2010 Subcontracts, Alternate 1 (Jun 2007)  FAR 52.244-5 Dec 1996 Competition in Subcontracting  FAR 52.244-6 Apr 2015 Subcontracts for Commercial Items  FAR 52.245-1 Apr 2012 Government Property  FAR 52.245-9 Apr 2012 Use and Charges  FAR 52.246-7 Apr 1996 Inspection of Research and Development – Fixed-Price  FAR 52.246-8 May 2001 Inspection of Research and Development – Cost-Reimbursement  FAR 52.246-23 Feb 1997 Limitation of Liability.  FAR 52.246-25 Feb 1997 Limitation of Liability—Services  FAR 52.248-1 Oct 2010 Value Engineering  

 

  44     FAR 52.249-2 Apr 2012 Termination for the Convenience of the Government (Fixed-Price)  FAR 52.249-6 May 2004 Termination (Cost-Reimbursement)  FAR 52.249-8 Apr 1984 Default (Fixed-Price Supply and Service)  FAR 52.249-9 Apr 1984 Default (Fixed-Price Research and Development)  FAR 52.249-14 Apr 1984 Excusable Delays  FAR 52.253-1 Jan 1991 Computer Generated Forms      (2) DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR  CHAPTER 3) CLAUSES:      HHSAR 352.203-70 Dec 2015 Anti-Lobbying  HHSAR 352.211-3 Dec 2015 Paperwork Reduction Act  HHSAR 352.222-70 Dec 2015 Contractor Cooperation in Equal Employment Opportunity Investigations  HHSAR 352.223-70 Dec 2015 Safety and Health  HHSAR 352.224-70 Dec 2015 Privacy Act  HHSAR 352.227-70 Dec 2015 Publications and Publicity  HHSAR 352.233-71 Dec 2015 Litigation and Claims  HHSAR 352.237-75 Dec 2015 Key Personnel  HHSAR 352.270-4a Dec 2015 Protection of Human Subjects  HHSAR 352.270-5b Dec 2015 Care of Live Vertebrate Animals  HHSAR 352.270-6 Dec 2015 Restriction on use of Human Subjects      ARTICLE I.2. ADDITIONAL FAR CLAUSES INCLUDED IN FULL TEXT    FAR 52.217-7 Option for Increased Quantity-Separately Priced Line Item (Mar 1989)    The Government may require the delivery of the numbered line item, identified in the Schedule as an option item, in  the quantity and at the price stated in the Schedule. The Contracting Officer may exercise the option by written notice  to the Contractor within 30 days. Delivery of added items shall continue at the same rate that like items are called for  under the contract, unless the parties otherwise agree.    FAR 52.217-9 Option to Extend the Term of the Contract (Mar 2000)    (a) The Government may extend the term of this contract by written notice to the Contractor within 30 Days  provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least  30 days before the contract expires. The preliminary notice does not commit the Government to an extension.    (b) If the Government exercises this option, the extended contract shall be considered to include this option clause.    (c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 8  years.    ARTICLE I.3. ADDITIONAL HHSAR CLAUSES – IN FULL TEXT    352.231-70 Salary rate limitation (December 2015)    (a) The Contractor shall not use contract funds to pay the direct salary of an individual at a rate in excess of the  Federal Executive Schedule Level II in effect on the date the funding was obligated.    (b) For purposes of the salary rate limitation, the terms “direct salary,” “salary,” and “institutional base salary,” have the  same meaning and are collectively referred to as “direct salary,” in this clause. An individual's direct salary is the  annual compensation that the Contractor pays for an individual's direct effort (costs) under the contract. Direct  salary excludes any income that  

 

  45   an individual may be permitted to earn outside of duties to the Contractor. Direct salary also excludes fringe  benefits, overhead, and general and administrative expenses (also referred to as indirect costs or facilities and  administrative costs). The salary rate limitation does not restrict the salary that an organization may pay an  individual working under a Department of Health and Human Services contract or order; it merely limits the portion  of that salary that may be paid with contract funds.    (c) The salary rate limitation also applies to individuals under subcontracts.    (d) If this is a multiple-year contract or order, it may be subject to unilateral modification by the Contracting Officer to  ensure that an individual is not paid at a rate that exceeds the salary rate limitation provision established in the  HHS appropriations act used to fund this contract.    (e) See the salaries and wages pay tables on the Office of Personnel Management website for Federal Executive  Schedule salary levels.  

 

  46   PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS    SECTION J - LIST OF ATTACHMENTS    The following documents are attached and incorporated in this contract:    1. Statement of Work, dated September 30, 2016, 10 pages    2. Invoice/Financing Instructions for Cost-Reimbursement Type Contracts    3. Invoice Instructions for Fixed-Priced Type Contracts    4. Sample Invoice Form    5. Research Patient Care Costs    6. Report of Government Owned, Contractor Held Property, 1 page.    7. Form SF-LLL, Disclosure of Lobbying Activities, 2 pages    8. Inclusion Enrollment Report, 5/01 (Modified OAMP: 10/01), 1 page  

 

September 29, 2016 Page 1      ATTACHMENT 1: STATEMENT OF WORK    NEXT GENERATION ANTHRAX VACCINE RFP 16-100-SOL-0015 AV7909 Anthrax Vaccine    1.1 Contractual Statement of Work        1.2Scope  The scope of work for this contract includes AV7909 development activities through licensure that fall into the  following areas: program management, nonclinical, clinical, regulatory, and chemistry, manufacturing, and controls  (CMC). The scope of work also includes activities to support post-marketing requirements.    1.3    Objective  The objective of this Statement of Work (SOW) is to conduct all necessary activities to advance the development of  AV7909 through Biologics License Application (BLA) submission and approval and post- marketing requirements.  Activities to meet the objective of this SOW fall in three separate contract line item number (CLIN):  • CLIN 0001 - Approval of Emergency Use Authorization (EUA), licensure, approval, and clearance of  product through the FDA (Base)  • CLIN 0001A – Conduct of a Phase 2 clinical [**] study  or other studies required by the FDA [**] (Option)  • CLIN 0002 - Initial purchase, storage, and delivery of product (Base)  • CLIN 0003 – Phase 4 post marketing requirements (Option)  • CLIN 0004 - Surge Capacity – Additional procurement of product (Option)    1.3 CLIN 0001 - Approval of Emergency Use Authorization (EUA), licensure, approval, and clearance of  product through the FDA (Base)  This section identifies representative tasks and sub-tasks for CLIN 0001 with associated WBS code for each task or  subtask.    [**] Program Management  Emergent shall provide program management activities. The activities shall include but are not limited to:    • Identification of and management to, distinct stages of the product development pathway that are gates for  Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan.  • Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of  product development activities for each stage with a budget (in direct costs) linked to each stage.  • Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the  scientific merit and technical feasibility of proceeding to the next stage of product development.  Preamble to the Statement of Work  Independently and not as an agent of the Government, the Contractor shall be required to furnish all the  necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the  Government, as needed to perform the Statement of Work submitted in response to RFP 16-100-SOL-  00015.  

 

September 29, 2016 Page 2      • Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated  effort to perform the work.  • Directing and overseeing subcontractors and consultants to assure successful performance of planned  activities within the cost and schedule constraints of the contract.  • Conducting performance measurement that shall include establishing an initial plan; defining measurable  parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a  detailed schedule that generates a critical path for the project; and a description of the cost-accounting  system used or intended to be used based on budget estimates to monitor all costs related to the contract  award for both Emergent and subcontractors on a real time basis.  • Manage contract activities in accordance with Earned Value Management. In this regard, Emergent  shall:  o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly  indicates the critical path to support product approval. The Integrated Master Project Plan shall  outline key, critical path milestones, with “Go/No-Go” decision criteria and a contract Work  Breakdown Structure (due within 90 days of contract award with updates as requested by the  Contracting Officer’s Representative (COR).  o Submit an updated Integrated Master Schedule in an approved format.  o Use principles of Earned Value Management System (EVMS) in the management of this contract.  o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to  the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award.  • Develop and maintain a risk management plan.  • Participate in regular meetings to coordinate and oversee the contracting effort.    [**] Non-Clinical Toxicology  Emergent shall conduct safety and toxicology of AV7909 using animal models following Good Laboratory Practice  guidelines (GLP: as defined in the U.S. Code of Federal Regulations, 21CFR Part 58), as appropriate. The activities  shall include but are not limited to:    [**]    [**] Non-Clinical Efficacy  Emergent shall conduct efficacy, pharmacokinetics/pharmacodynamics, bioavailability, solubility, formulation, dose,  route and schedule of the medical countermeasure using both in vitro and animal models following Good Laboratory  Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations, 21 CFR Part 58), as appropriate. The  activities shall include but are not limited to:                  [**]    [**] Clinical Evaluation  Emergent shall design and conduct Phase 2 and Phase 3 clinical studies in accordance with all Federal regulations  and Good Clinical Practice (GCP) guidelines. The activities shall include but are not limited to:  

 

September 29, 2016 Page 3      [**]    [**] Regulatory Activities  Emergent shall conduct all required regulatory activities to support submission of BLA licensure for AV7909. The  activities shall include but are not limited to:    [**]    [**] - Chemistry and Manufacturing Controls (CMC)  Emergent shall complete the manufacturing activities necessary to support BLA submission. The activities  shall include but are not limited to:    [**]    1.4CLIN 0001A - Conduct of a Phase 2 clinical [**] study or other studies required by the FDA [**] (Option)    This section identifies representative tasks and sub-tasks for CLIN 0001A with associated WBS code for each task or  subtask.    [**] Program Management  Emergent shall provide program management activities. The activities shall include but are not limited to:    • Identification of and management to, distinct stages of the product development pathway that are gates for  Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan.  • Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of  product development activities for each stage with a budget (in direct costs) linked to each stage.  • Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the  scientific merit and technical feasibility of proceeding to the next stage of product development.  

 

September 29, 2016 Page 4      • Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated  effort to perform the work.  • Directing and overseeing subcontractors and consultants to assure successful performance of planned  activities within the cost and schedule constraints of the contract.  • Conducting performance measurement that shall include establishing an initial plan; defining measurable  parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a  detailed schedule that generates a critical path for the project; and a description of the cost-accounting  system used or intended to be used based on budget estimates to monitor all costs related to the contract  award for both Emergent and subcontractors on a real time basis.  • Manage contract activities in accordance with Earned Value Management. In this regard, Emergent  shall:  o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly  indicates the critical path to support product approval. The Integrated Master Project Plan shall  outline key, critical path milestones, with “Go/ No Go” decision  criteria and a contract Work Breakdown Structure (due within 90 days of contract award with  updates as requested by the Contracting Officer’s Representative (COR).  o Submit an updated Integrated Master Schedule in an approved format.  o Use principles of Earned Value Management System (EVMS) in the management of this contract.  o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to  the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award.  • Develop and maintain a risk management plan.  • Participate in regular meetings to coordinate and oversee the contracting effort.    [**] Clinical Evaluation  Emergent shall design and conduct a Phase 2 clinical study in accordance with all Federal regulations and Good  Clinical Practice (GCP) guidelines unless other studies are required by the FDA [**]. The activities shall include, but  are not limited to:    • [**] - AVA.214 Phase 2 [**] Study    [**] - Chemistry and Manufacturing Controls (CMC)  Emergent shall complete the manufacturing activities necessary to support AVA.214 Phase 2 [**] Study. The  activities below are specific to conducting a Phase 2 [**] clinical study. If the FDA requires an alternate strategy  for [**], the activities below may no longer be applicable. Upon new guidance from the FDA, Emergent will update  the SOW accordingly.    [**]    1.5CLIN 0002 - Initial purchase, storage, and delivery of product (Base)  Emergent shall deliver 2,000,000 doses of AV7909 within [**] after EUA pre-authorization approval by FDA.  

 

September 29, 2016 Page 5      1.6 CLIN 0003 - Phase 4 post marketing requirements (Option)  [**].    Program Management  Emergent shall provide program management activities. The activities shall include but are not limited to:    • Identification of and management to, distinct stages of the product development pathway that are gates for  Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan.  • Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of  product development activities for each stage with a budget (in direct costs) linked to each stage.  • Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the  scientific merit and technical feasibility of proceeding to the next stage of product development.  • Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated  effort to perform the work.  • Directing and overseeing subcontractors and consultants to assure successful performance of planned  activities within the cost and schedule constraints of the contract.  • Conducting performance measurement that shall include establishing an initial plan; defining measurable  parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a  detailed schedule that generates a critical path for the project; and a description of the cost-accounting  system used or intended to be used based on budget estimates to monitor all costs related to the contract  award for both Emergent and subcontractors on a real time basis.  • Manage contract activities in accordance with Earned Value Management. In this regard, Emergent  shall:  o Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly  indicates the critical path to support product approval. The Integrated Master Project Plan shall  outline key, critical path milestones, with “Go/No Go” decision criteria and a contract Work  Breakdown Structure (due within 90 days of contract award with updates as requested by the  Contracting Officer’s Representative (COR).  o Submit an updated Integrated Master Schedule in an approved format.  o Use principles of Earned Value Management System (EVMS) in the management of this contract.  o Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to  the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award.  • Develop and maintain a risk management plan.  • Participate in regular meetings to coordinate and oversee the contracting effort.    [**]    1.7CLIN 0004 - Surge Capacity – Additional procurement of product (Option)  Emergent shall deliver up to 25 million dose regimens (equivalent to 50 million doses of AV7909). This option may  be triggered after EUA pre-authorization approval by FDA, which is currently linked to release of PPQ lots, and  deliveries will start within [**] after trigger.    1.8Reporting Requirements and Deliverables Reports  As part of the work to be performed under this contract, Emergent will prepare and deliver the following reports  throughout the period of performance.    Monthly Technical Progress Reports  On the fifteenth (15) day of each month for the previous calendar month, Emergent will submit to the COR and the  CO a Technical Progress Report covering the previous calendar month. The first reporting period consists of the first  full month of performance plus any fractional part of the initial month.  Thereafter, the reporting period will consist of each calendar month. The frequency of Technical Progress Reporting  will be determined by the CO and COR during negotiations of the contract. The format and type of Technical  Progress Report and Executive Summary will be provided by the COR. The Technical Progress Reports will  summarize progress for the reporting period, such as: management and administrative updates, technical progress,  

 

September 29, 2016 Page 6      issues, proposed work, manufacturing and supply chain management, and a summary of invoices. A Technical  Progress Report will not be required for the period when the same month Annual Progress Reports or a Final Report  are due. Emergent will submit one copy of the Technical Progress Report electronically via e-mail to the CO and  COR.    Annual Progress Reports  On the thirtieth (30th) calendar day following the last day of each reporting period, Emergent will submit to the COR  and the CO an Annual Progress Report. The first reporting period consists of the first full year of performance plus  any fractional part of the initial year. Thereafter, the reporting period shall consist of each calendar year. Annual  Progress Reports will summarize progress for the reporting period, such as: management and administrative updates,  technical progress, issues, proposed work, manufacturing and supply chain management, and a summary of invoices.  An Annual Progress Report will not be required for the period when the Final Technical Progress Report is due.    Draft Final Report and Final Report  Emergent will submit the Draft Final Progress Report forty-five (45) calendar days prior to the expiration date of the  contract and the Final Progress Report on or before the expiration date of the contract. These reports will include a  summation of the work performed and results obtained for execution of various studies or technical work packages  during the entire contract period of performance. This report will be in sufficient detail to describe comprehensively  the results achieved. An electronic copy of the Draft Final Report and Final Report will be submitted to the COR and  CO.    FDA Regulatory Agency Correspondence, Meeting Summaries, and Submissions  With regard to interactions with the FDA, Emergent shall:  • Forward the initial draft minutes to BARDA within five business days of any formal meeting with the  FDA or other regulatory agency, and forward the final minutes when available.  

 

September 29, 2016 Page 7      • Forward the initial draft minutes to BARDA within five business days of any informal meeting with the  FDA or other regulatory agency, and forward the final minutes when available and if applicable.  • Forward the dates and times of any meeting with the FDA and other regulatory agencies to BARDA as  soon as the meeting times are known and make arrangements for appropriate BARDA staff to attend  the meetings.  • Provide BARDA the opportunity to review and comment upon any documents to be submitted to the FDA or  other regulatory agency. Emergent will provide BARDA with five (5) business days in which to review and  provide comments prior to Emergent’s submission to the FDA.    Emergent will notify the COR and CO within 24 hours of all FDA arrivals to conduct site visits/audits by any  regulatory agency and provide the USG with an exact copy (non-redacted) of the FDA Form 483 and the  Establishment Inspection Report (EIR). Emergent will provide the COR and CO copies of the plan for addressing  areas of non-conformance to FDA regulations for Good Laboratory Practice (GLP) guidelines as identified in the  audit report, status updates during the plans execution, and a copy of all final responses to the FDA. Emergent will  also provide redacted copies of any FDA audits received from subcontractors that occur as a result of this contract or  for this product. Emergent will make arrangements with the COR for the appropriate BARDA representative(s) to be  present during the final debrief by the regulatory inspector.  

 

September 29, 2016 Page 8      Key Deliverables  A summary of Key Deliverables for this contract follow  No. Deliverable Description Due Date      01      Monthly Progress  Report  Shall include a description of the activities  during the reporting period and the activities  planned for the ensuing reporting period. The  first reporting period consists of the first full  month of performance plus any fractional part  of the initial month. Thereafter, the reporting  period shall consist of each calendar month.  Due on or before the 15th day of  each month following the end of each  reporting period. Monthly progress  reports are not required in the same  month Annual Progress reports or a  Final Report are due.      02      Annual Progress  Report  Shall include a summation of the activities  during the reporting period, and the activities  planned for the ensuing reporting period. The  first reporting period consists of the first full  year of performance plus any fractional part of  the initial year. Thereafter, the reporting period  shall consist of each calendar year.      Due on or before the 30th calendar day  following the end of each reporting  period.      03      Draft Final Progress  Report  To include a summation of the work performed  and results obtained for execution of various  studies or technical work packages during  entire contract period of performance. Shall be  in sufficient detail to describe comprehensively  the results achieved.      Due 45 Calendar days prior to the  expiration date of the contract.      04      Final Progress  Report  To include a summation of the work performed  and results obtained for execution of various  studies or technical work packages during  entire contract period of performance. Shall be  in sufficient detail to describe comprehensively  the results achieved.      Due on/before the expiration date of  the contract.                  05              FDA/Regulatory  Agency  Correspondence  and Meeting  Minutes  The Contractor shall forward initial draft  minutes and final draft minutes of any formal  or informal meeting with the FDA or other  regulatory agency. The contractor shall forward  the dates and times of any meeting with the  FDA and other regulatory agencies as soon  as the meeting times are known and make  arrangements for appropriate BARDA staff to  attend the meetings. The Contractor shall  provide BARDA the opportunity to review  and comment upon any documents to be  submitted to the FDA or other regulatory  agency. The Contractor shall forward SOPs  upon request from the COR. The contractor  shall notify the COR and CO within 24 hours  of all FDA arrivals to conduct sitevisits/audits  by any regulatory agency, and provide copies  of any associated reports, documentation, or  communication.              Due within 5 business days of each  meeting for Contractor’s minutes,  upon receipt of minutes from FDA/  regulatory agency, and upon request  from the COR or Co-COR.            06        Integrated Master  Project Plan (Critical  Path Milestones,  Work Breakdown  Structure, Risk  Mitigation Plan/  Matrix)  The contractor shall provide an Integrated  Master Plan (including tabular and Gantt forms)  to BARDA that clearly indicates the critical  path to annual deliverables (key, critical path  milestones, with “Go/No Go” decision criteria)  and Work Breakdown Structure (WBS) elements  that shall be discernable and consistent. The  contractor shall develop and maintain a risk  management plan that highlights potential  problems and/or issues that may arise during  the life of the contract, their impact on cost,  schedule and performance, and appropriate  remediation plans.          Due within 90 days of contract award.  Updates are due as requested by the  COR or Co-COR.    07 Technology  Packages  Technology packages developed under the  contract that includes complete protocols must  be submitted at the request of the BARDA COR.  Due upon request from the COR or  Co-COR.       

 

September 29, 2016 Page 9          No. Deliverable Description Due Date      08    Experimental  Protocols  The Contractor shall submit to the COR all  study/experiment/test plans, designs, and  protocols prior to execution for BARDA  approval or upon request by the COR or  Co-COR when required.    Due upon request from the COR or  Co-COR.          09        Annual/Final  Invention Report  All reports and documentation required by  FAR Clause 52.227-11, Patent Rights-  Ownership by the Contractor, including, but  not limited to, the invention disclosure report,  the confirmatory license, and the Government  support certification. If no invention is disclosed  or no activity has occurred on a previously  disclosed invention during the applicable  reporting period, a negative report shall be  submitted to the CO.      Annual Invention Report Due on or  before the 30th calendar day after the  completion of each reporting period.  Final Invention Report due on or  before the expiration of the contract.    10    Publications  Any manuscript or scientific meeting abstract  containing data generated under this contract  must be submitted to COR for review prior to  submission.  Due within 30 calendar days for  manuscripts prior to publication  and 15 calendar days for abstracts.      11      Press Releases  The Contractor agrees to accurately and  factually represent the work conducted  under this contract in all press releases. The  Contractor shall ensure the CO has received  and approved an advanced copy of any press  release not less than five (5) business days prior  to the issuance of any potential press release.    Reports/Notices due for approval to  the CO not less than five (5) business  days prior to the issuance of any  potential press release.    12    Security Report  The contractor shall report to the government  any activity or incident that is in violation of  established security standards or indicates the  loss or theft of government products    Due within 24 hours after occurrence  of an activity or incident.              13            Earned Value  Management  System  Requirements  Subject to the requirements under FAR  52.234-4 Earned Value Management System,  the Contract shall use principles of Earned  Value Management System (EVMS) in the  management of this contract (include this  plan as part of the monthly, annual, and final  reports). The Contractor shall also submit a  Performance Measurement Baseline Review  plan electronically via email to the CO and COR  for a PMBR to occur within 90 days of contract  award, and an Integrated Master Schedule  electronically via email as outlined in a format  agreed upon by BARDA to the COR and CO. The  Offeror shall deliver an Earned Value Contract  Performance Report on a monthly basis.              As detailed in Section F.3.2 Subpart F.  .  

 

September 29, 2016 Page 10         Milestone  #  WBS  #    Milestone Deliverables Summary (Details  as specified in the Deliverables)    Quantity  Estimated  Completion  Date                              CLIN 0001      1  [**] [**] [**] 1 Electronic Copy to  Contract Officer  Representative (COR);  1 Electronic Copy to  Contracting Officer (CO)  [**]  2 [**] [**] [**] See Above [**]  3 [**] [**] [**] See Above [**]  4 [**] [**] [**] See Above [**]  5 [**] [**] [**] See Above [**]  6 [**] [**] [**] See Above [**]  7 [**] [**] [**] See Above [**]    8  [**] [**] [**]   See Above  [**]  9 [**] [**] [**] See Above [**]  10 [**] [**] [**] See Above [**]  11 [**] [**] [**] See Above [**]  12 [**] [**] [**] See Above [**]  CLIN 0002 16 - Completion of delivery of 2  million doses of AV7909  Delivery of 2 million doses of  AV7909  See Above [**]      

 

HHSO100201600030C Emergent BioSolutions           ATTACHMENT #2    INVOICE/FINANCING REQUEST INSTRUCTIONS - FOR COST-REIMBURSEMENT TYPE CONTRACTS      Format: Payment requests shall be submitted on the Contractor’s self-generated form in the manner and format  prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard Form 1034, Public Voucher  for Purchases and Services Other Than Personal, may be used in lieu of the Contractor’s self-generated form provided  it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter with  the payment request.  Number of Copies: Payment requests shall be submitted in the quantity specified in the Invoice Submission  Instructions in Section G of the Contract Schedule.    Frequency: Payment requests shall not be submitted more frequently than once every two weeks in accordance with  the Allowable Cost and Payment Clause incorporated into this contract. Small business concerns may submit  invoices/financing requests more frequently than every two weeks when authorized by the Contracting Officer.    Cost Incurrence Period: Costs incurred must be within the contract performance period or covered by pre-contract  cost provisions.    Billing of Costs Incurred: If billed costs include (1) costs of a prior billing period, but not previously billed, or (2) costs  incurred during the contract period and claimed after the contract period has expired, the Contractor shall site the  amount(s) and month(s) in which it incurred such costs.    Contractor's Fiscal Year: Payment requests shall be prepared in such a manner that the Government can identify  costs claimed with the Contractor's fiscal year.    Currency: All BARDA contracts are expressed in United States dollars. When the Government pays in a currency  other than United States dollars, billings shall be expressed, and payment by the Government shall be made, in that  other currency at amounts coincident with actual costs incurred. Currency fluctuations may not be a basis of gain or  loss to the Contractor. Notwithstanding the above, the total of all invoices paid under this contract may not exceed the  United States dollars authorized.    Costs Requiring Prior Approval: Costs requiring the Contracting Officer's approval, including those set forth in an  Advance Understanding in the contract, shall be identified and reference the Contracting Officer's Authorization (COA)  Number. In addition, the Contractor shall show any cost set forth in an Advance Understanding as a separate line item  on the payment request.    Invoice/Financing Request Identification: Each payment request shall be identified as either:    (a) Interim Invoice/Contract Financing Request: These are interim payment requests submitted during the  contract performance period.    (b) Completion Invoice: The completion invoice shall be submitted promptly upon completion of the work, but no  later than one year from the contract completion date, or within 120 days after settlement of the final indirect  cost rates covering the year in which the contract is physically complete (whichever date is later). The  Contractor shall submit the completion invoice when all costs have been assigned to the contract and it  completes all performance provisions.    (c) Final Invoice: A final invoice may be required after the amounts owed have been settled between the  Government and the Contractor (e.g., resolution of all suspensions and audit exceptions).  

 

HHSO100201600030C Emergent BioSolutions           Preparation and Itemization of the Invoice/Financing Request: The Contractor shall furnish the information set  forth in the instructions below. The instructions are keyed to the entries on the Sample Invoice/Financing Request.    (a) Designated Billing Office Name and Address: Enter the designated billing office name and address, as  identified in the Invoice Submission Instructions in Section G of the Contract Schedule.    (b) Contractor's Name, Address, Point of Contact, VIN, and DUNS or DUNS+4 Number: Show the Contractor's  name and address exactly as they appear in the contract, along with the name, title, phone number, and e-mail  address of the person to notify in the event of an improper invoice or, in the case of payment by method other than  Electronic Funds Transfer, to whom payment is to be sent. Provide the Contractor’s Vendor Identification Number  (VIN), and Data Universal Numbering System (DUNS) number or DUNS+4. The DUNS number must identify the  Contractor’s name and address exactly as stated on the face page of the contract. When an approved  assignment has been made by the Contractor, or a different payee has been designated, provide the same          information for the payee as is required for the Contractor (i.e., name, address, point of contact, VIN, and DUNS).    (c) Invoice/Financing Request Number: Insert the appropriate serial number of the payment request.    (d) Date Invoice/Financing Request Prepared: Insert the date the payment request is prepared.    (e) Contract Number and Order Number (if applicable): Insert the contract number and order number (if  applicable).    (f) Effective Date: Insert the effective date of the contract or if billing under an order, the effective date of the order.    (g) Total Estimated Cost of Contract/Order: Insert the total estimated cost of the contract, exclusive of fixed-fee.  If billing under an order, insert the total estimated cost of the order, exclusive of fixed- fee. For incrementally  funded contracts/orders, enter the amount currently obligated and available for payment.    (h) Total Fixed-Fee: Insert the total fixed-fee (where applicable) or the portion of the fixed-fee applicable to  a particular invoice as defined in the contract.    (i) Two-Way/Three-Way Match: Identify whether payment is to be made using a two-way or three- way match. To  determine required payment method, refer to the Invoice Submission Instructions in Section G of the Contract  Schedule.    (j) Office of Acquisitions: Insert the name of the Office of Acquisitions, as identified in the Invoice Submission  Instructions in Section G of the Contract Schedule.    (k) Central Point of Distribution: Insert the Central Point of Distribution, as identified in the Invoice Submission  Instructions in Section G of the Contract Schedule.    (l) Billing Period: Insert the beginning and ending dates (month, day, and year) of the period in which costs were  incurred and for which reimbursement is claimed.    (m) Amount Billed - Current Period: Insert the amount claimed for the current billing period by major cost element,  including any adjustments and fixed-fee. If the Contract Schedule contains separately  

 

HHSO100201600030C Emergent BioSolutions           priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by  major cost element) for each line item.    (n) Amount Billed - Cumulative: Insert the cumulative amounts claimed by major cost element, including any  adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract  line item(s) on the payment request and include a separate breakdown (by major cost element) for each line  item.    (o) Direct Costs: Insert the major cost elements. For each element, consider the application of the paragraph  entitled "Costs Requiring Prior Approval" on page 1 of these instructions.    (1) Direct Labor: Include salaries and wages paid (or accrued) for direct performance of the contract. List  individuals by name, title/position, hourly/annual rate, level of effort (actual hours or % of effort), breakdown  by task performed by personnel, and amount claimed.    (2) Fringe Benefits: List any fringe benefits applicable to direct labor and billed as a direct cost. Do not  include in this category fringe benefits that are included in indirect costs.    (3) Accountable Personal Property: Include any property having a unit acquisition cost of  $5,000 or more, with a life expectancy of more than two years, and sensitive property regardless of cost  (see the HHS Contractor's Guide for Control of Government Property)(e.g. personal computers). Note this is  not permitted for reimbursement without pre-authorization from the CO.    On a separate sheet of paper attached to the payment request, list each item for which reimbursement is  requested. Include reference to the following (as applicable):    - Item number for the specific piece of equipment listed in the Property Schedule, and    - COA number, if the equipment is not covered by the Property Schedule.    The Contracting Officer may require the Contractor to provide further itemization of property having specific  limitations set forth in the contract.    (4) Materials and Supplies: Include all consumable material and supplies regardless of amount. Detailed line- item breakdown (e.g. receipts, quotes, etc.) is required.    (5) Premium Pay: List remuneration in excess of the basic hourly rate.    (6) Consultant Fee: List fees paid to consultants. Identify consultant by name or category as set forth in the  contract or COA, as well as the effort (i.e., number of hours, days, etc.) and rate billed.    (7) Travel: Include domestic and foreign travel. Foreign travel is travel outside of Canada, the United States  and its territories and possessions. However, for an organization located outside Canada, the United  States and its territories and possessions, foreign travel means travel outside that country. Foreign travel  must be billed separately from domestic travel.    (8) Subcontract Costs: List subcontractor(s) by name and amount billed. Provide subcontract  invoices/receipts as backup documentation. If subcontract is of the cost-reimbursement variety, detailed  breakdown will be required. Regardless, include backup documentation (e.g. subcontractor invoices,  quotes, etc.).  

 

HHSO100201600030C Emergent BioSolutions           (9) Other: Include all other direct costs not fitting into an aforementioned category. If over  $1,000, list cost elements and dollar amounts separately. If the contract contains restrictions on any cost  element, that cost element must be listed separately.    (p) Cost of Money (COM): Cite the COM factor and base in effect during the time the cost was incurred and  for which reimbursement is claimed, if applicable.    (q) Indirect Costs: Identify the indirect cost base (IDC), indirect cost rate, and amount billed for each indirect cost  category.    (r) Fixed-Fee: Cite the formula or method of computation for fixed-fee, if applicable. The fixed-fee must be  claimed as provided for by the contract.    (s) Total Amounts Claimed: Insert the total amounts claimed for the current and cumulative periods.    (t) Adjustments: Include amounts conceded by the Contractor, outstanding suspensions, and/or disapprovals  subject to appeal.    (u) Grand Totals    (v) Certification of Salary Rate Limitation: If required by the contract (see Invoice Submission Instructions  in Section G of the Contract Schedule), the Contractor shall include the following certification at the bottom  of the payment request:    “I hereby certify that the salaries billed in this payment request are in compliance with the Salary Rate Limitation  Provisions in Section H of the contract.”    **Note the Contracting Officer may require the Contractor to submit detailed support for costs claimed on payment  requests. Every cost must be determined to be allocable, reasonable, and allowable per FAR Part 31.  

 

HHSO100201600030C Emergent BioSolutions           ATTACHMENT #3    INVOICE/FINANCING REQUEST INSTRUCTIONS FOR FIXED PRICE TYPE CONTRACTS    General The Contractor shall submit vouchers or invoices as prescribed herein.    Format Standard Form l034, Public Voucher for Purchases and Services Other Than Personal, and Standard Form  l035, Public Voucher for Purchases and Services Other than Personal--Continuation Sheet, and the payee's letterhead  or self-designed form should be used to submit claims for reimbursement.    Number of Copies: As indicated in the contract.    Frequency Invoices submitted in accordance with the Payment Clause shall be submitted monthly upon delivery of  goods or services unless otherwise authorized by the Contracting Officer.    Preparation and Itemization of the Invoice The invoice shall be prepared as follows:    (a) Designated Billing Office and address:  HHS/ASPR/BARDA  330 Independence Ave, Room G640 Washington DC  20201  ATTN: Contracting Officer    (b) Invoice Number    (c) Date of Invoice    (d) Contract number and date    (e) Payee's name and address. Show the Contractor's name (as it appears in the contract), correct address, and the  title and phone number of the responsible official to whom payment is to be sent. When an approved assignment has  been made by the Contractor, or a different payee has been designated, then insert the name and address of the  payee instead of the Contractor.    (f) Description of goods or services, quantity, unit price, (where appropriate), and total amount.    (g) Charges for freight or express shipments other than F.O.B. destination. (If shipped by freight or express and  charges are more than $25, attach prepaid bill.)    (h) Equipment - If there is a contract clause authorizing the purchase of any item of equipment, the final invoice must  contain a statement indicating that no item of equipment was purchased or include a completed form HHS-565,  Report of Capitalized Nonexpendable Equipment.    Currency: Where payments are made in a currency other than United States dollars, billings on the contract shall be  expressed, and payment by the United States Government shall be made, in that other currency at amounts coincident  with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the Contractor. Notwithstanding  the above, the total of all invoices paid under this contract may not exceed the United States dollars authorized.    

 

HHSO100201600030C Emergent BioSolutions         ATTACHMENT #4 - SAMPLE INVOICE FORM  Company Name    This invoice represents reimbursable costs for the period from    Expenditure Category  Amount Billed   Current Cumulative Contract Value  Direct Costs:     Direct Labor     Fringe Benefits 0.00%     Total Labor Costs:          Overhead 0.00%          Travel     Subcontracts     Consultant Fees     Materials and Supplies     Other     Total Direct Costs          G&A Rate 0.00%          Subtotal:          Fixed Fee 0.0          Total Amount Claimed          Adjustments          Grand Total $ -    I certify that all payments requested are for appropriate purposes and in accordance with the contract.      Name/signature of signatory authority for invoicing  Designated Billing Office Name and Address:    DHHS/OS/ASPR/AMCG  Attn: Contracting Officer  200 C St., S.W.    Washington, D.C. 20201    Contractor’s Address and Contact Information:                POC: Name of accountant or COO or signatory authority for invoice  Title: Phone:  E-Mail:    TIN:  DUNS #:  Invoice/Finance Number:  Date Invoice Prepared:  Contract No. and Title:  Effective Date & Period of Performance:  Total Estimated Cost of Order:  Office of Acquisitions:  Contracting Officer (insert name here)  Office of Acquisitions Management, Contracts,  Grants (AMCG)        Central Point of Distribution:  and  

 

HHSO100201600030C Emergent BioSolutions           ATTACHMENT #5    RESEARCH PATIENT CARE COSTS    (a) Research patient care costs are the costs of routine and ancillary services provided to patients participating  in research programs described in this contract.    (b) Patient care costs shall be computed in a manner consistent with the principles and procedures used by the  Medicare Program for determining the part of Medicare reimbursement based on reasonable costs. The Diagnostic  Related Group (DRG) prospective reimbursement method used to determine the remaining portion of Medicare  reimbursement shall not be used to determine patient care costs.  Patient care rates or amounts shall be established  by the Secretary of HHS or his duly authorized representative.    (c) Prior to submitting an invoice for patient care costs under this contract, the Contractor must make every  reasonable effort to obtain third party payment, where third party payors (including Government agencies) are  authorized or are under a legal obligation to pay all or a portion of the charges incurred under this contract for  patient care.    (d) The Contractor must maintain adequate procedures to identify those research patients participating in this contract  who are eligible for third party reimbursement.    (e) Only those charges not recoverable from third party payors or patients and which are consistent with the terms and  conditions of the contract are chargeable to this contract.  

 

     Attachment 6    REPORT OF GOVERNMENT OWNED, CONTRACTOR HELD PROPERTY  CONTRACTOR: CONTRACT NUMBER:  ADDRESS: REPORT DATE:  ADDRESS1:   ADDRESS2: FISCAL YEAR:  CITY:   STATE:  ZIP:     CLASSIFICATION BEGINNING OF  PERIOD  ADJUSTMENTS END OF PERIOD   #ITEMS VALUE GFP  ADDED  CAP  ADDED  DELETIONS #ITEMS VALUE  LAND >=$25K         LAND <$25K         OTHER REAL >=$25K         OTHER REAL <$25K         PROPERTY UNDER CONST  >=$25K          PROPERTY UNDER CONST  <$25K          PLANT EQUIP >=$25K         PLANT EQUIP <$25K         SPECIAL TOOLING >=$25K         SPECIAL TOOLING <$25K         SPECIAL TEST EQUIP >=$25K         SPECIAL TEST EQUIP <$25K         AGENCY PECULIAR >=$25K         AGENCY PECULIAR <$25K         MATERIAL >=$25K  (CUMULATIVE)        PROPERTY UNDER MFR  >=$25K          PROPERTY UNDER MFR  <$25K          SIGNED BY:     SIGNATURE     DATE SIGNED:      NAME PRINTED     Email      TITLE     TELEPHONE      Report of Government Owned, Contractor Held Property (Rev 10/2014)  

 

     ________   ________  _____________   _____________  _______________________  Attachment 7  DISCLOSURE OF LOBBYING ACTIVITIES                          Approved by OMB  Complete this form to disclose lobbying activities pursuant to 31 U.S.C. 1352 0348-0046  (See reverse for public burden disclosure.)  1. Type of Federal Action:  a. contract  b. grant  c. cooperative agreement  d. loan  e. loan guarantee  f. loan insurance  2. Status of Federal Action:  a. bid/offer/application  b. initial award  c. post-award  3. Report Type:  a. initial filing  b. material change  For Material Change Only:  year quarter  date of last report  4. Name and Address of Reporting Entity:  Prime Subawardee  Tier ,  if known :          Congressional District, if known :   5. If Reporting Entity in No. 4 is a Subawardee, Enter Name  and Address of Prime:            Congressional District, if known :  6. Federal Department/Agency: 7. Federal Program Name/Description:      CFDA Number, if applicable :______________  8. Federal Action Number, if known : 9. Award Amount, if known :  $  10. a. Name and Address of Lobbying Registrant b. Individuals Performing Services (including address if  ( if individual, last name, first name, MI ): different from No. 10a )  (last name, first name, MI ):    11. Information requested through this form is authorized by title 31 U.S.C. section  1352.  This disclosure  of lobbying activities is  a material  representation  of fact  upon which reliance was placed by the tier above when this transaction was made  or entered into. This disclosure is required pursuant to 31 U.S.C. 1352. This  information will be available for public inspection. Any person who fails to file the  required disclosure  shall be subject to a civil penalty of not less than $10,000 and  not more than $100,000 for each such failure.  Signature:      Print Name:       Title:      Telephone No.: Date:       Federal Use Only: Authorized for Local Reproduction  Standard Form LLL (Rev. 7-97)        PRINT  

 

     INSTRUCTIONS FOR COMPLETION OF SF-LLL, DISCLOSURE OF LOBBYING ACTIVITIES  This disclosure form shall be completed by the reporting entity, whether subawardee or prime Federal recipient, at the initiation or receipt of a covered  Federal action, or a material change to a previous filing, pursuant to title 31 U.S.C. section 1352. The filing of a form is required for each payment or  agreement to make payment to any lobbying entity for influencing or attempting to influence an officer or employee of any agency, a Member of  Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with a covered Federal action. Complete all  items that apply for both the initial filing and material change report. Refer to the implementing guidance published by the Office of Management and  Budget for additional information.      1. Identify the type of covered Federal action for which lobbying activity is and/or has been secured to influence the outcome of a covered Federal  action.    2. Identify the status of the covered Federal action.    3. Identify the appropriate classification of this report. If this is a follow up report caused by a material change to the information previously  reported, enter the year and quarter in which the change occurred. Enter the date of the last previously submitted report by this reporting  entity for this covered Federal action.    4. Enter the full name, address, city, State and zip code of the reporting entity. Include Congressional District, if known. Check the appropriate  classification of the reporting entity that designates if it is, or expects to be, a prime or subaward recipient. Identify the tier of the subawardee,  e.g., the first subawardee of the prime is the 1st tier. Subawards include but are not limited to subcontracts, subgrants and contract awards  under grants.    5. If the organization filing the report in item 4 checks "Subawardee," then enter the full name, address, city, State and zip code of the prime  Federal recipient. Include Congressional District, if known.    6. Enter the name of the Federal agency making the award or loan commitment. Include at least one organizational level below agency name, if  known. For example, Department of Transportation, United States Coast Guard.    7. Enter the Federal program name or description for the covered Federal action (item 1). If known, enter the full Catalog of Federal Domestic  Assistance (CFDA) number for grants, cooperative agreements, loans, and loan commitments.    8. Enter the most appropriate Federal identifying number available for the Federal action identified in item 1 (e.g., Request for Proposal (RFP)  number; Invitation for Bid (IFB) number; grant announcement number; the contract, grant, or loan award number; the  application/proposal control number assigned by the Federal agency). Include prefixes, e.g., "RFP-DE-90-001."    9. For a covered Federal action where there has been an award or loan commitment by the Federal agency, enter the Federal amount of the  award/loan commitment for the prime entity identified in item 4 or 5.    10. (a) Enter the full name, address, city, State and zip code of the lobbying registrant under the Lobbying Disclosure Act of 1995 engaged by the  reporting entity identified in item 4 to influence the covered Federal action.    (b) Enter the full names of the individual(s) performing services, and include full address if different from 10 (a). Enter Last Name, First Name,  and Middle Initial (MI).    11. The certifying official shall sign and date the form, print his/her name, title, and telephone number.    According to the Paperwork Reduction Act, as amended, no persons are required to respond to a collection of information unless it displays a valid OMB  Control Number. The valid OMB control number for this information collection is OMB No. 0348-0046. Public reporting burden for this collection of  information is estimated to average 10 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and  maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other  aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction  Project (0348-0046), Washington, DC 20503.        

 

     Cumulative Inclusion Enrollment Report  This report format should NOT be used for collecting data from study  participants.  Study Title:  Comments:      Racial Categories  Ethnic Categories     Total Not Hispanic or Latino Hispanic or Latino Unknown/Not Reported Ethnicity    Female    Male  Unknown/  Not  Reported    Female    Male  Unknown/  Not  Reported    Female    Male  Unknown/  Not  Reported  American Indian/  Alaska Native             0    Asian             0  Native Hawaiian or  Other Pacific  Islander             0  Black or African  American             0    White             0  More Than One  Race             0  Unknown or Not  Reported             0    Total    0    0    0    0    0    0    0    0    0    0    PHS 398 / PHS 2590 (Rev. 08/12 Approved Through 8/31/2015) OMB No. 0925-0001/0002  Page  Cumulative Inclusion Enrollment Reportemergent600030cmodificat

      Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of  information that the registrant treats as private or confidential.  Double asterisks denote omissions.  AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES   1 6  2. AMENDMENT/MODIFICATION NO.   0001  3.  EFFECTIVE DATE  See Block 16C    4. REQUISITION/PURCHASE NO.     5. PROJECT NO. (If applicable)    6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6)   CODE ASPR-BARDA  ASPR-BARDA  200 Independence Ave., S.S.  Room 640-G  Washington, DC 20201  ASPR-BARDA  200 Independence Ave., S.S.  Room 638-G  Washington, DC 20201  8.  NAME AND ADDRESS OF CONTRACTOR (No., Street, county, State and ZIP Code)     (x) 9A. AMENDMENT OF SOLICITATION NO.    EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.   EMERGENT PRODUCT DEVELOPMENT GAITHE  300 PROFESSIONAL DR # 100  GAITHERSBURG MD 208793419      9B. DATED (SEE ITEM 11)     x 10A. MODIFICATION OF CONTRACT/ORDER NO.  HHSO100201600030C   10B. DATED (SEE ITEM 13)  CODE    1365869 FACILITY CODE       09/30/2016  11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  □ The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers                     □ is extended, □ is not extended.  Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:  (a) By completing  Items 8 and 15, and returning ____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or  (c) By separate letter or  telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED  FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.  If by virtue of this amendment you desire  to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment,  and is received prior to the opening hour and date specified.  12. ACCOUNTING AND APPROPRIATION DATA (If required)    See Schedule  13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER  NO. IN ITEM 10A.    B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  appropriation date, etc) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).   C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:        X  D. OTHER (Specify type of modification and authority)    FAR 52.243-2 Changes – Cost Reimbursement  E. IMPORTANT:  Contractor   □ is not, ⊠ is required to sign this document and return     2    copies to the issuing office.  14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)  Tax ID Number:  [**]  DUNS Number:  [**]  The purpose of this modification is to modify ARTICLES B.2 BASE PERIOD, B.3. OPTION PRICES,  B.5. ADVANCE UNDERSTANDINGS, and SECTION 1 - CONTRACT CLAUSES.    Funds Obligated Prior to this Modification: $198,705,042  Funds Obligated with Mod #1: $0  Total Funds Obligated to Date: $198,705,042    Expiration Date: September 29,2021  Period of Performance: 09/30/2016 to 09/29/2021  Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.  15A. NAME AND TITLE OF SIGNER (Type or print)  Barbara Solow                                      SVP Research and Development  16A. NAME OF CONTRACTING OFFICER   CHRISTOPHER SCOTT  15B. CONTRACTOR/OFFEROR  /s/ Barbara Solow       (Signature of person authorized to sign)  15C. DATE SIGNED    Mar 14, 2017  16B. UNITED STATES OF AMERICA  By  /s/ Christopher Scott     (Signature of Contracting Officer)  16C. DATE SIGNED    3/16/17  NSN 7540-01-152-8070 STANDARD FORM 30 (Rev. 10-83)  Previous edition unusable  Prescribed by GSA    FAR (48 CFR) 53.243 

 

  2    ARTICLE B.2. BASE PERIOD is hereby modified as follows:    CLIN Period of  Performance  Supplies/ Services Total Est. Cost Fixed Fee  (7%)  Total Cost Plus  Fixed Fee      COST REIMBURSEMENT      0001  (Base)  09/30/2016 –  09/29/2021  Licensure, approval, and clearance  of product through the FDA  [**] [**] [**]      FIRM FIXED PRICE      CLIN Period of  Performance  Supplies/ Services Units (# of  Doses)  Unit Price ($) Total ($)  0002  (Base)  09/30/2016 –  09/29/2021  Initial Purchase, Storage, and  Delivery of Product  3,000,000 [**] [**]  Total  CLINS  1&2  09/30/2016 –  09/29/2021  See Above Descriptions   $198,705,042  (Funded)  [**]    ARTICLE B.3. OPTION PRICES is hereby modified as follows:    CLIN Period of  Performance  Supplies/ Services Total Est. Cost Fixed Fee Total Cost  Plus Fixed  Fee ($)      COST REIMBURSEMENT     0001A  (Option  Quantity)  [**] Phase II [**] Study or  studies required by the FDA [**]  [**] [**] [**]  CLIN Period of  Performance  Supplies/ Services Total Est. Cost Fixed Fee Total Cost  Plus Fixed  Fee ($)      FIXED PRICE     0003  (Option  Quantity)  [**] Phase IV post marketing  commitments /Requirements  (This is an option that may or  may not be exercised during the  base period as determined by  the need and as established by  the FDA)  N/A N/A [**]    CLIN Period of  Performance  Supplies/ Services Units (# of  Product)  FY 2018  Unit Price  ($)  Total ($)  0004A  (Option  Quantity)  [**] Additional Surge Capacity (EUA)       7,500,000 to  [**]  [**] [**]  

 

  3      0004B  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  7,500,000 to  [**]  [**] [**]  0004C  (Option  Quantity)  [**] Additional Surge Capacity (EUA) [**] [**] [**]  0004D  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  [**] [**] [**]  0004E  (Option  Quantity)  [**] Additional Surge Capacity (EUA) [**] [**] [**]  0004F  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  [**] [**] [**]  0004G  (Option  Quantity)  [**] Additional Surge Capacity (EUA) [**] [**] [**]  0004H  (Option  Quantity)  [**] Additional Surge Capacity  (Licensure)  [**] [**] [**]    [**]    ARTICLE B.5. ADVANCE UNDERSTANDINGS is hereby modified as follows:    h. Option CLINS    If procurement for CLIN 4 occurs after FY 2018, the following chart illustrates the dose  prices to be used:    Units (# of Doses) FY 2019 Unit  Price ($)  FY 2020 Unit  Price ($)  FY 2021 Unit  Price ($)  7,500,000 to  [**]  [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]  [**] [**] [**] [**]    [**] 

 

  4    The USG reserves the right to re-negotiate the option CLINS based on availability of  funds and feedback received from the FDA.      SECTION I - CONTRACT CLAUSES    ARTICLE I.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY  1998) is hereby modified to add FAR 52.219-9 as follows:    This contract incorporates the following clauses by reference, with the same force and effect as if  they were given in full text. Upon request, the Contracting Officer will make their full text available.  Also, the full text of a clause may be accessed electronically at these addresses:  https://www.acquisition.gov/FAR/ . HHSAR Clauses at:  http://www.hhs.gov/policies/hhsar/subpart352.html .    General Clauses for Cost-Reimbursement/Fixed Price Research and Development Contract    (1) FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:      Reg Clause Date Clause Title  FAR 52.202-1 Nov 2013 Definitions  FAR 52.203-3 Apr 1984 Gratuities  FAR 52.203-5 May 2014 Covenant Against Contingent Fees  FAR 52.203-6 Sep 2006 Restrictions on Subcontractor Sales to the Government  FAR 52.203-7 May 2014 Anti-Kickback Procedures  FAR 52.203-8 May 2014 Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity  FAR 52.203-10 May 2014 Price or Fee Adjustment for Illegal or Improper Activity  FAR 52.203-12 Oct 2010 Limitation on Payments to Influence Certain Federal Transactions  FAR 52.203-13 Oct 2015 Contractor Code of Business Ethics and Conduct  FAR 52.203-14 Oct 2015 Display of Hotline Poster(s)    FAR    52.203-17    Apr 2014 Contractor Employee Whistleblower Rights and Requirement To Inform  Employees of Whistleblower Rights  FAR 52.204-4 May 2011 Printed or Copied Double-Sided on Postconsumer Fiber Content Paper  FAR 52.204-7 Jul 2013 System for Award Management  FAR 52.204-10 Oct 2015 Reporting Executive Compensation and First-Tier Subcontract Awards  FAR 52.204-13 Jul 2013 System for Award Management Maintenance    FAR    52.209-6    Oct 2015 Protecting the Government's Interests When Subcontracting With Contractors  Debarred, Suspended, or Proposed for Debarment  FAR 52.209-10 Nov 2015 Prohibition on Contracting with Inverted Domestic Corporations  FAR 52.210-1 Apr 2011 Market Research  FAR 52.215-2 Oct 2010 Audit and Records – Negotiation  FAR 52.215-8 Oct 1997 Order of Precedence - Uniform Contract Format  FAR 52.215-10 Aug 2011 Price Reduction for Defective Cost or Pricing Data  FAR 52.215-11 Aug 2011 Price Reduction for Defective Certified Cost or Pricing Data—Modifications.  FAR 52.215-12 Oct 2010 Subcontractor Certified Cost or Pricing Data  FAR 52.215-13 Oct 2010 Subcontractor Certified Cost or Pricing Data—Modifications  FAR 52.215-15 Oct 2010 Pension Adjustments and Asset Reversions  FAR 52.215-17 Oct 1997 Waiver of Facilities Capital Cost of Money    FAR    52.215-18    Jul 2005 Reversion or Adjustment of Plans for Postretirement Benefits (PRB) other than  Pensions  FAR 52.215-19 Oct 1997 Notification of Ownership Changes    FAR    52.215-21    Oct 2010 Requirements for Certified Cost or Pricing Data and Data Other Than Certified  Cost or Pricing Data -Modifications  FAR 52.215-23 Oct 2009 Limitations on Pass-Through Charges  FAR 52.216-7 Jun 2013 Allowable Cost and Payment  FAR 52.216-8 Jun 2011 Fixed Fee  FAR 52.219-8 Oct 2014 Utilization of Small Business Concerns  

 

  5    FAR 52.219-9 Nov 2016 Small Business Subcontracting Plan  FAR 52.219-28 July 2013 Post-Award Small Business Program Representation  FAR 52.222-1 Feb 1997 Notice to the Government of Labor Disputes  FAR 52.222-2 Jul 1990 Payment for Overtime Premiums  FAR 52.222-3 Jun2003 Convict Labor  FAR 52.222-21 Apr 2015 Prohibition of Segregated Facilities  FAR 52.222-26 Apr 2015 Equal Opportunity  FAR 52.222-35 Oct 2015 Equal Opportunity for Veterans  FAR 52.222-36 Jul 2014 Equal Opportunity for Workers with Disabilities  FAR 52.222-37 Feb 2016 Employment Reports on Veterans  FAR 52.222-40 Dec 2010 Notification of Employee Rights Under the National Labor Relations Act    FAR    52.222-43    May 2014 Fair Labor Standards Act and Service Contract Labor Standards—Price  Adjustment (Multiple Year and Option Contracts)  FAR 52.222-50 Mar 2015 Combating Trafficking in Persons  FAR 52.222-54 Oct 2015 Employment Eligibility Verification  FAR 52.223-6 May 2001 Drug-Free Workplace  FAR 52.223-18 Aug 2011 Encouraging Contractor Policy to Ban Text Messaging While Driving  FAR 52.224-1 April 1984 Privacy Act Notification  FAR 52.224-2 April 1984 Privacy Act  FAR 52.225-13 Jun 2008 Restrictions on Certain Foreign Purchases  FAR 52.227-1 Dec 2007 Authorization and Consent, Alternate 1 (APR 1984)  FAR 52.227-2 Dec 2007 Notice and Assistance Regarding Patent and Copyright Infringement  FAR 52.227-3 Apr 1984 Patent Indemnity  FAR 52.227-11 May 2014 Patent Rights – Ownership by the Contractor  FAR 52.227-14 May 2014 Rights in Data - General  FAR 52.227-16 Jun 1987 Additional Data Requirements  FAR 52.228-7 Mar 1996 Insurance – Liability to Third Persons  FAR 52.229-3 Feb 2013 Federal, State and Local Taxes  FAR 52.230-2 Oct 2015 Cost Accounting Standards  FAR 52.230-6 June 2010 Administration of Cost Accounting Standards  FAR 52.232-1 Apr 1984 Payments  FAR 52.232-2 Apr 1984 Payments under Fixed-Price Research and Development Contracts  FAR 52.232-8 Feb 2002 Discounts for Prompt Payment  FAR 52.232-9 Apr 1984 Limitation on Withholding of Payments  FAR 52.232-11 Apr 1984 Extras  FAR 52.232-17 May 2014 Interest  FAR 52.232-20 Apr 1984 Limitation of Cost  FAR 52.232-23 May 2014 Assignment of Claims  FAR 52.232-25 Jul 2013 Prompt Payment  FAR 52.232-33 Jul 2013 Payment by Electronic Funds Transfer--System for Award Management  FAR 52.233-1 May 2014 Disputes  FAR 52.233-3 Aug 1996 Protest After Award, Alternate I  FAR 52.233-4 Oct 2004 Applicable Law for Breach of Contract Claim  FAR 52.242-1 Apr 1984 Notice of Intent to Disallow Costs  FAR 52.242-3 May 2014 Penalties for Unallowable Costs  FAR 52.242-4 Jan 1997 Certification of Final Indirect Costs  FAR 52.242-13 Jul 1995 Bankruptcy  FAR 52.243-1 Aug 1987 Changes - Fixed-Price Alternate V (Apr 1984).  FAR 52.243-2 Aug 1987 Changes—Cost-Reimbursement Alternate V (Apr 1984).  FAR 52.243.6 Apr 1984 Change Order Accounting  FAR 52.243-7 Apr 1984 Notification of Changes  FAR 52.244-2 Oct 2010 Subcontracts, Alternate 1 (Jun 2007)  FAR 52.244-5 Dec 1996 Competition in Subcontracting  FAR 52.244-6 Apr 2015 Subcontracts for Commercial Items  FAR 52.245-1 Apr 2012 Government Property  FAR 52.245-9 Apr 2012 Use and Charges  

 

  6    FAR 52.246-7 Apr 1996 Inspection of Research and Development – Fixed-Price  FAR 52.246-8 May 2001 Inspection of Research and Development – Cost-Reimbursement  FAR 52.246-23 Feb 1997 Limitation of Liability.  FAR 52.246-25 Feb 1997 Limitation of Liability—Services  FAR 52.248-1 Oct 2010 Value Engineering  FAR 52.249-2 Apr 2012 Termination for the Convenience of the Government (Fixed-Price)  FAR 52.249-6 May 2004 Termination (Cost-Reimbursement)  FAR 52.249-8 Apr 1984 Default (Fixed-Price Supply and Service)  FAR 52.249-9 Apr 1984 Default (Fixed-Price Research and Development)  FAR 52.249-14 Apr 1984 Excusable Delays  FAR 52.253-1 Jan 1991 Computer Generated Forms        All other terms and conditions of this contract remain unchanged.    End of Modification #1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]